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The issue with maintaining stability of compounds during storage and 
transportation has been universal across many fields such as clinical, pharmaceutical, food 
industry and especially in forensic laboratories where case backlogs hinder immediate 
analysis of samples upon collection. This study compares various storage conditions and 
analyzes changes in compound stability over 28 days. The various storage conditions 
compared in this study are temperature (+4 °C and -20 °C); water sample and urine sample 
and solid state (loading onto Solid Phase Extraction cartridges) and storing in its liquid 
state (present in the urine or water sample). 51 compounds were analyzed in this study 
belonging to pharmaceutical and hormone classes. Two Dimensional Liquid 
Chromatography was used for separation allowing the analysis of varied compounds in 
terms of chemistry. Mass Spectrometry was used for detection of these compounds. This 
study conclusively helped determine that there is no significant difference in stability of 42 
out of 51 of these compounds on comparing them in solid versus liquid state over a period 
of 28 days. This helps determine that Solid Phase Extraction (SPE) cartridges can be used 
as an alternative for storage and transportation of these compounds. 46 compounds showed 
no significant difference in +4 and -20 °C temperature storage conditions as well. Despite 
vi 
not including a wash step during sample preparation between loading and elution, 11 out 
of 51 compounds did not show suppression or enhancement due to matrix effect. This study 
not only highlights the importance of sample preparation prior to analysis but also shows 
how SPE technique could help maintain stability of compounds during storage. In future 
studies, stability changes using SPE for long term storage could provide beneficial results 
to conclude if SPE techniques can provide an advantage over liquid state for a period longer 
than a month. 
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1. INTRODUCTION 
1.1 Stability of Compounds 
The issue with maintaining stability of compounds during storage and transport has 
been universal across many fields such as clinical, pharmaceutical, food industry and 
especially in forensic laboratories where case backlogs hinder immediate analysis of 
samples upon collection. In order to tackle these problems many studies have been 
conducted to observe compound stability changes under various conditions and in various 
matrices ranging from water samples to biological fluids.1 The matrix of the sample poses 
its own set of challenges when it comes to maintaining compound stability. There are a 
number of factors that contribute towards the stability of a compound such as, pH of the 
sample, temperature at which sample is stored, the material of the sample container, 
exposure to light and bacterial contamination. 2 pH dependent factors affect urine samples 
the most as the pH is highly variable, pH 4-8.3 As the complexity of the matrix increases 
the compounds are less likely to remain stable. According to a stability study of designer 
drugs such as MDA, MDMA and MDEA it was observed that under -20°C conditions, 
these drugs are stable up to 13 weeks in whole blood and up to 21 weeks in water, urine 
and serum.4  
One of the main causes of compound degradation is oxidation and hydrolysis in 
liquid matrices.  Biological fluids such as urine are water based and can cause rapid 
degradation of analyte present by hydrolysis.5 In order to avoid hydrolysis, the water 
component of urine must be separated from the analyte and this can be achieved using solid 
phase extraction cartridges. This technique has been used in previous studies to test 
2 
compound stability of many compounds in aqueous matrices. In other studies, pH, 
temperature and light have also been considered to be factors that cause degradation. It has 
been confirmed in a study testing for fluoroquinolones that direct sunlight exposure has 
proven to cause degradation in river samples.1   Freezing and thawing of compounds 
directly in their liquid matrix have been studied and has served as a common short term 
storage method. However, the issues that have occurred with freezing samples is that these 
samples degrade within three to four months.  
According to a study done on piperazines it was found that most compounds 
showed highest degradation between day 91 and day 182 of storing at 4°C and -20°C.6 
Other than this, the logistics of storing many samples in frozen liquid condition is 
impractical. In order to counter these problems an alternative for long term storage in the 
form of Solid Phase Extraction (SPE) cartridges has been tested in this study. 
The types of compound degradation that are commonly found to occur are, 7first, long term 
stability that evaluates the storage of samples under same conditions and temperature that 
allows for storage at least as long as that of standards. Second, freeze thaw stability which 
involves determination of number of cycles of freezing and thawing that are allowed before 
substantial degradation. Third, bench top stability or in-process stability that evaluates the 
stability of the compound during sample preparation. It involves maintaining stability at 
room temperature and to determine the time taken for sample preparation and if addition 
of preservatives is required. Lastly, sample stability in processed samples, these samples 
have undergone sample preparation and are ready for injections. Delays in analysis of 
extracted samples could lead to degradation.7 In this particular study, long term storage of 
3 
eight class of compounds are being determined and compared to freeze thaw stability.7 
1.2 Factors Affecting Compound Stability 
There are two forms of compound degradation one being reversible and the other 
being irreversible. Reversible degradation leads to structural or conformational changes 
that can be reversed under normal storage conditions and sample treatment, whereas 
irreversible degradation is mostly due to structural changes and therefore it is important to 
identify the factors that affect the degradation of compounds.8 Temperature, exposure to 
light, pH, oxidation and enzymes are among external factors. It is imperative to take 
precautions to control these factors such as, storage at low temperatures, keeping samples 
away from direct exposure of light or using UV filtered light, using buffers to stabilize pH, 
addition of reducing agents to prevent oxidation and lastly addition of enzyme inhibitors 
prevent chemical and enzymatic degradation.8 
In case of photosensitive compounds, they usually absorb UVA light, these 
compounds most typically have double bonds such as alkenes, aromatic compounds or 
hetero-aromatic compounds.8 Some even absorb UVC light from germicidal lamps that are 
used for decontamination. Lomefloxacin which belongs to class of quinolones is 
photosensitive and many other compounds in this class are susceptible to light 
degradation.8 Using UV filtered lights and amber glass vials for storage could be a possible 
solution.8 
Temperature is a factor that affects compound stability the most. Many studies have 
been carried out that determine freezing of samples at -20°C slows degradation 
considerably. 4,6  However, the major contribution towards compound instability is thawing 
4 
after freezing. As a precautionary measure, it is recommended to thaw in cold conditions 
and limit the freeze and thaw cycles to a minimum.8 Yet as long as the compound is stored 
in a liquid state the need to freeze and thaw will only further the damage. 
Conditions of pH must be kept stable. During analysis, through liquid 
chromatography the compounds are prepped under organic solvent at particular pH 
conditions that can alter the pka of the compound in order to carry out trap and elution 
procedures. Further a study has been found that suggests that the pH of biological matrices 
such as blood, urine and plasma change over time from a pH of 7.2 -7.4 to 8.8 at room 
temperatures.9 It was found that use of phosphate buffer at a pH of 7.4 helps decrease the 
loss of compound from 60% at a pH of 8.3 to 12 % at a pH of 7.4 and 40% at a pH of 8.0.9 
Acidic compounds such as telmisartan, ibuprofen and mycophenolic acids can form acyl 
glucuronide metabolites that rapidly hydrolyze at a pH of 7.4 in aqueous solutions, so it is 
important to maintain pH. 10 In case of compounds that have ester functional groups such 
as clopidogrel, their acidic metabolites form acyl glucoronides that are cleaved by esterases 
in plasma. If these esters are prepped using methanol or ethanol, the metabolites may be 
alkylated and converted back to the parent form. This causes an increase in parent 
compound concentration in the matrix during storage.11 
Oxidation reactions cause compound degradation. Auto-oxidation  involves the 
uncatalyzed reaction of compound with molecular oxygen (O2).
12  Most oxidation 
processes occur in the form of chain reactions that are initiated either through auto-
oxidation by molecular oxygen or by photolysis or hemolytic thermal cleavage. Transition 
metals such as Cu2+ and Fe3+ also react either with molecular oxygen or organic and 
5 
inorganic substrates that lead to formation of free radicals which cause a series of chain 
reactions that degrade the compound. Antioxidants such as ascorbic acid, thiols or phenols 
that act as reducing agents terminate these chain reactions. Alternatively, chelating agents 
such as ethylenediaminetetradiacetic acid (EDTA) form complexes with the transition 
metal ions and prevent them from causing oxidation reactions.12 
Enzyme Degradation of compounds occurs mainly due to enzymes present in the 
matrix, mainly in blood. In order to counter enzyme degradation, addition of sodium 
fluoride has been found to be helpful. Mainly compounds containing ester functional group 
are more likely to degrade by enzymatic degradation such as 17β- estradiol.8 
The chances of hydrolysis increase when compounds are stored in its liquid form. 
This reaction occurs due the consumption of a water molecule while breaking a down a 
complex molecule into its simpler form. Hydrolysis occurs in many biological mechanisms 
and is likely to occur in biological fluids such as urine and blood therefore making it 
unfavorable to freeze samples in its matrix. 
1.3 Classes of Compounds Analyzed 
The three classes of compounds analyzed have been banned by World Anti-Doping 
Agency (WADA), an international independent body whose objective is scientific 
research, education and developing and monitoring the WADA code. They were 
established in 1999 and the below mentioned compounds are listed by WADA as banned 
substances during athletic competitions or otherwise.13 However, these compounds are 
analyzed for stability studies as that has become a growing concern in laboratories.  
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 Hormones and Metabolic Modulators  
These class of compounds are further subcategorized into Aromatase inhibitors 
(Letrozole and Aminogluthemide); Selective estrogen selective modulators (SERM) 
(Raloxifene, Toremifene and Tamoxifene); anti-estrogenic substances (Clomiphene and 
Cyclofenil) and Metabolic Modulators (Meldonium). These compounds have major side 
effects that include but are not limited to cardiac problems; osteoporosis and even 
complications due to insulin overdose, which causes health issues. These compounds are 
popularly used in sports doping to mask anabolic agents and controlling blood glucose 
levels in diabetic patients. 14 There aren’t many stability studies on these class of 
compounds. They are mainly analyzed for clinical applications due to their widespread use 
in hormonal regulation and to alter metabolites to their less potent form.15 
 
 Synthetic Cannabinoids  
Synthetic Cannabinoids are structurally similar to cannabinoids and can bind to the 
same receptor CB1 or CB2 to mimic the effect 11-nor-9-carboxy-Δ
9-tetrahydrocannabinol 
glucuronide (THC) in marijuana.16 Synthetic cannabinoids have stronger ability to bind to 
the receptors and therefore give greater side effects than THC such as anxiety, seizures, 
agitation and tachycardia. The JWH group of compounds were named after John W 
Huffman who synthesized the compounds to study the effect of THC for research purposes. 
These compounds are now readily sold in the market as “spice” or “K2” and their difficulty 
in detection in urine has made them increasingly popular as a drug of abuse.16 Cannabinoids 
pose a great problem while maintaining their stability, they oxidize and bind to the 
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containers they are stored in, even in frozen samples and reconversion of THC to the free 
acid metabolite also poses as a problem in maintaining stability of these compounds.7, 17 
 
 Hormones  
Hormones are typically used in sports doping for muscle growth. There are growth 
hormones, anabolic hormones and steroid hormones. The compounds analyzed under this 
class are steroid hormones as they are produced from cholesterol, they are further classified 
as Progestogens. These hormones maintain pregnancy. Progesterone is the major 
progestogen present in the human body. Other progestin are synthetic derivatives of 
progesterone that are used for medicinal purposes. They are mainly used in hormonal 
treatment or contraception , to suppress effects of other hormones.18 
 
The following class of compounds are a list of pharmaceutical classes that have been 
analyzed for stability studies: 
Sulfas  
Sulfonamide drugs were among the first antibiotics to be discovered. They target 
dihydropteroate synthase (DHPS) enzyme found in bacteria. DHPS is an important enzyme 
in folic acid biosynthesis pathway. It catalyzes conversion of 6-hydroxymethyl-7,8-
dihydropterin pyrophosphate and p-amino benzoic acid (PABA) to 7,8-dihydropteroate. 
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Sulfa drugs attach to DHPS at the PABA site and block this reaction thereby limiting 
growth of many bacteria and eukaryotic pathogens.19 
 
 Macrolides  
Macrolides are a group of antibiotics. Erythromycin was the first discovered 
macrolide which is produced by Saccharopolyspora erythraea. The other macrolides like 
clarithromycin and azithromycin are semisynthetic derivatives. Macrolides are composed 
of 14 (Erythromycin and clarithromycin), 15 (azithromycin) or 16 (spiramycin) membered 
lactones and via glycosidic bonds, amino acids and/or neutral sugars are attached to it.20 
 
Quinolones  
Quinolones are synthetic agents that have antimicrobial properties and were 
developed to treat bacterial infections. The older analogs such as nalidixic acid were altered 
structurally to form newer quinolones such Norfloxacin, Nadifloaxacin and the other 
compounds that are analyzed in this study. The new quinolones differ structurally from the 
older analogs because of the fluorine atom at position 6 and the piperazinyl or pyrrolidinyl 
substituent at position 7 of the quinolone backbone.21 
 
1.4 Solid Phase Extraction (SPE) 
SPE is a technique that is commonly used for extraction of analyte of interest from 
matrices. SPE cartridges, 96 well plates or 47-97 mm flat disks serve as a basic 
chromatography model using the principles of solid-liquid extraction in order to remove 
9 
interferences from complex matrices prior to chromatography and detection. SPE 
cartridges, as used in this study, are packed with sorbent and a liquid is passed through it 
usually under vacuum to control the flow rate.22 The analyte of interest is trapped in the 
pores of the sorbent while the interferences are flushed out in the wash step and then the 
compound of interest is collected in the elution solvent, this is called Captive SPE. SPE 
occurs in six steps, first is the pretreatment step which may or may not be required 
depending on the sample. For biological fluids a protein crash technique may be applied to 
remove the large protein molecules that could clog the cartridge. The second step is 
conditioning using organic solvent that allows the compound to enter the pores of the 
sorbent. A dry or de-wetted pore will not let the compound enter the pore for proper 
retention. After conditioning with organic solvent, it is equilibrated with aqueous solvent 
that ensures the sample is loaded as in reverse phase, samples are loaded in aqueous matrix. 
When the actual sample is added onto the sorbent it is called loading step and occurs after 
equilibration. The ensures that the compound of interest is retained on the sorbent. A wash 
step is added after loading to remove all interferences that could cause poor 
chromatography. Lastly the compound of interest that retained on the sorbent during 
loading is eluted using organic solvent in reverse phase conditions. There are many forms 
of SPE such as Normal Phase, Reversed Phase SPE and Ion exchange SPE.22  
The type of SPE technique selected depends on the property of the compound of 
interest based on which extraction is carried out.22 The sorbent material Silica C8 (n-
octylsilyl), C18 (n-octadecylsilyl) or HLB (Hydrophobic Lipophilic Balance) are among 
many that can be used in reverse phase chromatography. Silica is the most commonly used 
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sorbent and is used commonly for normal phase chromatography due to its polar property, 
when silica is unbound, it reacts with water to form hydrophilic silanol. However, when 
hydrocarbon C8 or C18 are bound to silica, they act as a support giving it a non-polar 
property making them ideal for reverse phase applications. Silica based sorbents have a 
limitation that does not allow them to be used at pH beyond the range of 2- 8 as the silica 
particles dissolve. In order to overcome this limitation, HLB a copolymer of 
divinylbenzene (lipophilic monomer) and n-vinylpyrrolidone (hydrophilic monomer) is 
used. Divinylbenzene gives it reverse phase property for nonpolar analyte retention. It 
provides a balance between hydrophilic and lipophilic properties which allows it to resist 
changes under a wide range of pH shift from pH 1- 14. The hydrophilic monomer 
vinylpyrrolidone prevents the sorbent from drying out quickly, this allows the analyte to 
retain better even if air is passed through while using a vacuum manifold that causes de-
wetting in silica based sorbents. HLB is also comparatively more retentive than silica based 
sorbents provides better recovery of analyte..22 
The method development aspect of SPE is crucial as that decides how efficiently 
the analyte of interest is recovered. The selection of the appropriate sorbent, loading pH 
and elution solvent are most important.23 On selecting the sorbent, the cartridge size is 
selected and accordingly the hold-up volume of the loading solution is selected which is 
affected by many factors such as, dimensions of the packed bed and the particle size of 
sorbent, the interstitial volume, the liquid volume in the pores of sorbent particle and lastly 
the volume of the outlet. Prior to loading, the cartridges are conditioned and equilibrated 
in order to wet the sorbent, this allows the analyte to enter the pores of the sorbent for better 
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retention. For Reverse Phase, the sorbent is then loaded using aqueous solvent with the 
sample at a pH that keeps the analyte of interest in neutral state (below its pka for acids 
and above its pka for bases). This allows analyte to retain on the sorbent. Then wash steps 
are carried out to remove interferences that retain either more weakly or strongly than the 
analyte depending on their retention factor (k). Lastly the analyte is eluted using organic 
solvents at a pH that ionizes the compound and lowers its attraction to the sorbent and 
therefore elutes.23  
 
1.5 Instrumentation Theory 
 1.5.1 Liquid Chromatography 
The concept of Chromatography deals with separation of compounds based on their 
chemical properties.24 In Reversed Phase liquid chromatography, the separation takes place 
based on the compound hydrophobicity. The stationary phase is the sorbent that retains the 
compound of interest that it has affinity for, while the mobile phase carries the compounds 
that do not have affinity for stationary phase. In reverse phase, the stationary phase is non 
polar and the mobile phase is polar, this allows non polar analytes to retain while polar 
compounds elute. The opposite of this is Normal Phase Liquid Chromatography which has 
a polar stationary phase and non-polar mobile phase.24 
There are different types of Liquid Chromatography techniques, one being HPLC 
(High Performance Liquid Chromatography) with typical internal diameter (ID) range of 
4.6 mm and 3.5 µm (microns) in particle size, in which pumps are used to push liquid 
mobile phases through sorbent packed columns under high pressure.24 HPLC uses a 
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pressure of 6000 psi. Further advancement in technology led to UPLC (Ultra Performance 
Liquid Chromatography) that has columns that are 1.7 µm (microns) in particle size, having 
a typical ID of  2.1 mm and can handle pressures up to 15,000 psi resulting in better 
resolution, speed and sensitivity.24 
The basic working of a UPLC and HPLC is that a solvent or mobile phase is pushed 
through a column with the help of pumps that deliver the solvent at a set flow rate usually 
in milliliters per minute. 24 The elution solvent flows through a column packed with sorbent 
that acts as a stationary phase for retaining the compounds. The solvent elutes the 
compounds in their ionized or neutral form from the stationary phase. The elution strength 
of the solvent determines the elution of each compound at different time points and this is 
denoted in the form of retention time (amount of time in minutes that it takes for each 
compound to detach from the stationary phase). The use of gradient LC system allows for 
the change in concentration of the elution solvent, this allows separation of a sample 
containing compounds ranging in their chromatographic polarity. The elution 
concentration is gradually increased to elute the strongly retained compounds. On the other 
hand, the isocratic elution uses only one concentration of a pure or mixture elution solvent.  
Upon elution the compound is detected by a detector, usually a mass spectrometer. 24 
 
1.5.2 Mass Spectrometry 
The mass spectrometer is coupled with the LC system and used for detection of 
compounds.25 The mass spectrometer has an ion source, a mass analyzer and a detector. 
The main function of a source is to ionize the compounds by adding or removing a proton 
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to a neutral species. Many forms of ionization techniques are used but the most widely used 
is Electrospray ionization where the solution containing compound of interest is dispersed 
as a fine aerosol spray in order to convert compounds from liquid form to gas-ion form for 
detection in the mass spectrometer. When the analyte of interest is in its liquid form they 
are nebulized or broken down into smaller droplet sizes. On applying high temperature, the 
droplet size decreases further due to evaporation of the excess solvent surrounding the 
analyte molecule and this is known as desolvation.  It then passes through a capillary with 
applied voltage (3000 V) and a charged droplet is formed and due to an opposite charge 
being applied to the droplet, the analyte of interest releases out of the charged droplet in 
the form of a fine aerosol spray that are sucked in by a cone with applied voltage. The 
analyte of interest has now entered the mass spectrometer on conversion from a liquid form 
to gas ion form which then enters the mass analyzer. The mass analyzer consists of 
quadrupoles, that are a set of four parallel metal rods that have an electric current of 
opposing charge applied to them that creates a fluctuating electric field. The ionized 
molecules that pass through the quadrupoles are separated based on their mass to charge 
ratio. The voltage of the quadrupole can be set to allow ions only having a particular mass 
to charge ratio to be allowed to pass through and get detected, while the other ions are 
deflected. The detected ions are represented in the form of a mass spectrum showing a plot 
of mass to charge ratio against signal intensity of each ion. In case of a Triple Quadrupole 
Mass Spectrometer the mass analyzer consists of three sets of quadrupoles. The first set of 
quadrupole (Q1) allows for the ionized compounds to enter as precursor ions or parent ions 
that are detected. The second set of quadrupole (Q2) only acts as a collision cell, the 
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precursor ions collide with inert gases resulting in fragmentation into product ions or 
daughter ions that are detected in the third quadrupole (Q3). In case of Multiple Reaction 
Monitoring (MRM), the Q1 and Q3 are set are particular masses to detect product ions 
produced from certain precursor ions. 25 
 
1.5.3 Two Dimensional Liquid Chromatography 
The term “Two Dimensional Liquid Chromatography” is coined based on the two 
separate liquid phase systems that exist independent of each other, one being loading and 
the other being elution.26 Two dimensional chromatography have two columns, the trap 
column, in the first dimension, has larger particle size that traps the compound of interest 
when loaded under aqueous conditions. In the second dimension, there is an analytical 
column having a smaller particle size that helps in improving resolution of compounds 
separated in the first dimension. In order to load compounds in high organic solvents, a 
dilution method is included as analytes prefer the mobile phase under organic conditions 
and are unable to retain to the column. It allows 100% organic extract to be loaded without 
having to add an evaporation and reconstitution step. The dilution ratio of 1:20 is used. 
Then the elution solvent takes the analyte off the first dimension and passes it through the 
second dimension that offers better resolution as it has a smaller particle size compared to 
the trap. This is called the trap and elute method with AT- column dilution. 26 It is these 
advantages over one dimensional chromatography that have made 2DLC popular for 
proteomics and metabolomics applications as these have thousands of constituents at 
15 
varying concentrations and make for complex samples that require 2DLC for efficient 
separation.27 
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2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Classes Developed for Analysis 
Six classes were selected for analysis; each class has between eight to ten 
compounds. The different classes were Hormones and Metabolic Modulators, 
Cannabinoids, Sulfas, Macrolides, Quinolones and Hormones.  
 
Hormones and Metabolic Modulators  
Seven compounds were analyzed under Hormones and Metabolic Modulators: 
Levonorgestrel, Aminogluthemide, Cyclofenil, Letrozole, Raloxifene, Tamoxifen, 
Toremifene and Clomiphene. (Figure 1 and Figure 2). 
 




Figure 2.  Structures of Hormones and Metabolic Modulators II 28 
 
Synthetic Cannabinoids  
 Five compounds were analyzed under Synthetic Cannabinoids:  JWH-018, 
AM2201, AB-PINACA, 5F-PB-22 and JWH-073. (Figure 3). 
 




Twelve compounds were analyzed under Sulfas: Sulfadiazine, Sulfamethizine, 
Flumequin, Indapamide, Sulfamethoxazole, Chlorpropamide, Chlorthalidone, 
(Diacetoxyiodo)benzene, Carbendazim, Sulfamethizole, Sulfasoxizole and Tolbutamide. 
(Figure 4). 
 
Figure 4.  Structures of Sulfas 28 
 
Macrolides  
Eight compounds were analyzed under Macrolides: Erythromycin, Clarithromycin, 




Figure 5.  Structures of Macrolides 28 
 
Quinolones  
Eight compounds were analyzed under Quinolones: Ciprofloxacin, Enoxacin, 
Lomefloxacin, Pefloxacin, Nadifloxacin, Norfloxacin, Ofloxacin, and Levofloxacin. 
(Figure 6). 
 




Ten compounds were analyzed with the Hormones:17 hydroxy-progesterone, 6α 
methyl prednisolone, Medroxyprogesterone, Triamicinolone diacetate, Triamicinolone 
acetonide, cortisone-21 acetate, Medroxyprogestrone acetate, Cortisone, Progesterone and 




Figure 7.  Structures of Hormones 28 
 
2.1.2 Standards and Reagents 
The compounds used for analysis were obtained from three Companies. 
Levonorgestrel, Aminogluthemide, Cyclofenil, Letrozole, Raloxifene, Tamoxifen, 
Toremifene, Clomiphene, JWH-018, AM2201, AB-PINACA, JWH-073, 6α methyl, 
Medroxyprogesterone, Triamicinolone acetonide, Cortisone-21 acetate, 
Medroxyprogesterone acetate and Hydrocortisone were obtained from Cayman Chemical 
Company (Ann Arbor, MI, USA). Sulfadiazine, Sulfamethizine, Flumequin, Indapamide, 
Sulfamethoxazole, Chlorpropamide, Chlorthalidone, (Diacetoxyiodo)benzene, 
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Carbendazim, Sulfamethizole, Sulfasoxizole, Tolbutamide, Erythromycin, 
Clarithromycin, Roxithromycin, Lincomycin, Spiramycin, Azithromycin, Dirithromycin, 
Clindamycin, Ciprofloxacin, Enoxacin, Lomefloxacin, Pefloxacin, Nadifloxacin, 
Norfloxacin, Ofloxacin, Levofloxacin, 17 hydroxy-progesterone, Cortisone and 
Progesterone were obtained from Sigma-Aldrich (St. Louis, MO, USA). 5F-PB-22, 
Triamicinolone diacetate was obtained from Lipomed (Cambridge, MA, USA). The 
solvents used for this analysis were methanol (MeOH), acetonitrile (ACN), ammonium 
hydroxide (NH4OH), and formic acid (FA). All solvents were Optima grade and obtained 
from Thermo Fisher Scientific (Waltham, MA, USA). Except FA was from Sigma-Aldrich 
(St. Louis, MO, USA). MilliQ grade water were used for this analysis which was obtained 
from EMD Millipore Sigma (Darmstadt, Germany). 
 
2.1.3 Instrumentation and Software 
An ACQUITY UPLC® (Waters Corporation, Milford, MA, USA) was utilized in 
the LC part of the instrument. The 2D LC system consists of three pumps which are the 
loading pump; dilution pump and elution pump. The loading pump, loads the samples from 
the injection loop into a mixer at a rate of 0.1 ml/min. The diluter pump, pumps water into 
the mixer at a rate of 2.0 ml/min. This dilution allows trapping of a 100 % organic extract 
to be retained on a trap material on first dimension. The third pump utilized was an elution 
pump, containing both an organic and aqueous fluid that gradually shift the gradient 
towards 95% organic and 5% aqueous. The detector, Xevo Triple Quadrupole (TQS) 
(Waters Corporation) mass spectrometer was used for analysis of all class of compounds. 
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The software utilized was MassLynx© version 4.2 and TargetLynx© version 4.2 (Waters 
Corporation). MassLynx© was used to observe the mass spectra and chromatograms 




2.2.1 Multiple Reaction Monitoring Optimization  
Infusions or Multiple Reaction Monitoring (MRM) are carried out in order to 
provide the Mass Spectrometry (MS) information about the parent ion and the daughter 
ions produced that helps it recognize a particular compound. A 1 mg/ml solution is first 
prepared by measuring 3 – 10 mg of the compound and dissolving it in equal volume of 
methanol. The 1 mg/ml (milligrams per milliliter) solution is then utilized to further make 
10 micrograms per milliliter (µg/ml) solution in 50:50 water: acetonitrile at pH 3, pH 7 and 
pH 10 by adding 10 µl of Formic acid and Ammonium hydroxide additives for acidic and 
basic pH respectively. The compounds are prepared at three pH conditions to select the pH 
condition that gives the highest intensity for each compound. The solutions are made in 2 
ml vial which is directly infused into the MS. The parent ion is detected under MS1 scan 
mode in the first quadrupole. The precursor ion then passes through the second quadrupole 
or the collision cell, where it is pressurized with argon gas and fragmented to produce 
product ions. The product ions then enter the third quadrupole where they are selectively 
filtered and then sent to the detector. The two most intense product ions are selected during 
the MRMs by analyzing the spectra. This is done by increasing the collision energy and 
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selecting the two most intense peaks for daughter ions and the collision energy at which 
the highest intensity was produced. The capillary voltage, desolvation temperature, 
desolvation gas rate, source temperature and cone gas rate were kept at constants of 3.0 
kilovolts (kV), 250°C, 450 liters per hour (L/hr), 150°C and 150 L/hr, respectively for 
Infusions. During Chromatography the desolvation temperature is kept at 450°C and the 
desolvation gas rate is kept at 1100 L/hr while the rest of the values remain the same.  
 
2.2.2 Chromatography Method Development 
One stock solution mixture was prepared for each class of compounds for 
chromatography method development. Each solution contained every compound from its 
assigned class, forming a final concentration for each compound, of 10 micrograms per 
milliliter (µg/mL). Each stock solution mixture was used to prepare solutions of lower 
concentration using serial dilutions. This resulted in 10 nanograms per milliliter (ng/mL) 
solutions prepared in Methanol (MeOH), Acetonitrile (ACN) and MilliQ water. 
These solutions were analyzed on 36 different methods with different combinations 
of trap columns, loading conditions and elution conditions. The injection volume for each 
sample was kept at a constant 50 µl. Samples were loaded onto the trap column at a rate of 
0.1 ml/min which were further diluted at a rate of 2.0 ml/min. From this column, the 
samples were eluted at a rate of 0.5 mL/min with a gradient that starts from 95% water and 
5% organic (3 to 8 minutes) and held at 95% organic for one minute, before returning on a 
declining gradient back to 95% water and 5% organic. The total run time is 10 minutes. 
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Thirty-six different methods involved permutations and combinations of four 
variables for each class of compounds. These methods involved comparing two different 
elution solvents: MeOH and ACN, three different loading pH levels: 3, 7, and 10; and two  
different elution pH level: a low of pH 3 and a high of pH 10, along with three different 
trap columns in the order of decreasing retention strength, a Waters ACQUITY UPLC 
hydrophilic-lipophilic balance (HLB), 2.1 x 30 mm, 20 µm; a Waters ACQUITY UPLC 
ethylene bridged hybrid (BEH) C18, 2.1 x 30 mm, 10 µm; and a Waters ACQUITY UPLC 
BEH C8, 2.1 x 30 mm, 10 µm. As seen in Figure 8. Formic acid was used to create the 
acidic conditions and Ammonium Hydroxide was used to create basic conditions. The 
analytical column was kept constant, with a Waters ACQUITY UPLC BEH C18, 2.1 x 
50mm, 1.7 µm.  
Figure 8. 6 X 6 Method Optimization Scheme29 
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Each class of compound is injected three times and the chromatograms for the third 
injection is analyzed for method development. It takes about 48 hours to acquire all the 
data for all 36 methods and about 48 hours more to analyze all the chromatograms and 
select the method that works best for all compounds in that class. In order to select the 
optimal method, each compound in that class is designated a color code, red being no 
signal; yellow being non-Gaussian peaks such as splits, broad peaks, tailing and leading 
peaks; lastly, Green is designated as Gaussian peaks and the intensity of the peaks is noted. 
The method having green with highest intensities for all compounds in that class is chosen 
as the optimal method for that class.  
 
 2.2.3 Sample Preparation 
Selecting Spiking Concentration of Each Compound 
In order to select the concentration for each compound that gives an intense signal 
meeting the cutoff e5 to e7 intensity, standards of each class of compounds were spiked at 
10 ng/ml, 1 ng/ml and 0.1 ng/ml in methanol and acetonitrile. These spiked solutions were 
analyzed using chromatography at their respective chosen methods. The concentration at 
which each compound gives between an e5 and e7 signal intensity is picked. The Table 1 















Cyclofenil  0.1 
Clomiphene 0.1 
  






Cyclofenil  0.1 
Clomiphene 0.1 
  











































Hormones   
6 methyl prednisolone 10 
Triamcinolone diacetate 10 
cortisone-21 acetate 10 
Triamicinolone acetonide 10 










Preparing Dilutions for Each Class Using Chosen Spiking Concentrations 
After the spiking concentrations were chosen, the dilutions were made from 1 
mg/ml solutions to the concentration chosen for each compound. The final dilution contains 
compounds at their respective chosen concentration being 10, 1 or 0.1 ng/ml in methanol, 
acetonitrile and water solutions.  
 
Carryover Management 
As it was seen in the analysis the peak of the compounds analyzed in the previous 
class appeared in all six blanks before moving onto the next class. This meant that adding 
six blanks between classes wasn’t sufficient to remove all compounds of the previous class 
before analyzing the next class. This could lead to the peaks seen in the previous injection 
being carried over in the next injection. In order to reduce the number of blanks being 
added between injections and to avoid carryover, the methods were changed by adding a 
reconditioning method. The overall run time of each injection had been increased from 10 
minutes to 11 minutes. At 3 minutes the valve position would change from position 1 to 2 
allowing the elution solvent to flow through the trap column to elute the compounds from 
it and carry it to the analytical column but at 6.8 minutes a reconditioning solvent is pumped 
at 2 ml/min from the loader and dilutor pumps. Reconditioning solvent removes the 
residual compound from the trap column which couldn’t be removed during the elution 
step. Reconditioning and elution is being carried out at the same time till 9.0 minutes. Then 
from 9.0 minutes to 10.8 minutes the system is returning to its original flow rate of 2.0 
ml/min for dilutor and 0.1 ml/min for loader pumps. Since the reconditioning step is 
introduced, the number of blanks added between each sample reduces to two. This 
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decreases the overall runtime for an entire list and reduces chances of carryover. In order 
to test if the carryover management works to reduce carryover, the final standard dilution 
prepared as discussed in the previous section was analyzed by adding three blanks before 
and six blanks after the three injections of each standard. The Figure 9 shown below shows 
no carryover occurred in the six blanks for compound Aminogluthemide after using 
carryover method versus not using carryover method. This confirmed that the 
reconditioning method was effective and similar results were seen for all compounds. 
 
Figure 9. MeOH Blanks Showing no Carryover After Injections of Class Hormones 
and Metabolic Modulators I Standard Using the Carryover Management method 
(Right) and MeOH Blanks Showing Peaks for Aminogluthemide Without Using 





Selecting Elution Solvent for SPE Technique 
SPE technique was carried out using 60mg 3cc Oasis® HLB (Waters Corporation).  
HLB is a copolymer of divinylbenzene and n-vinylpyrrolidone. It provides a balance 
between hydrophilic and lipophilic properties which allows it to resist changes under a 
wide range of pH shift. The copolymer prevents the sorbent from drying out quickly and 
provides better recovery of analyte. HLB is also comparatively more retentive than silica 
based sorbents. The samples were loaded in aqueous state at 10 ppb, 1 ppb and 0.1 ppb 
concentrations of compounds in that particular class. The load was collected to make sure 
no breakthrough occurs. Figure 10 below shows for class Synthetic Cannabinoids load, that 
no breakthrough has occurred as no peaks of these compounds can be seen. This means 
that the compounds have successfully retained onto the sorbent. 
Figure 10. Synthetic Cannabinoids Compounds Show no Breakthrough During 
Loading Step 
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In order to determine which elution solvent gives the most recovery, six elution 
solvents were used for each class of compound, ACN pH 3, 7 and 10 and MeOH pH 3, 7 
and 10 were analyzed. Figure 11 shows the chromatograms for Aminogluthemide in Class 
Hormones and Metabolic Modulators I in each of the different elution solvent. MeOH gives 
better peak shape than ACN does. This makes MeOH a more favorable elution solvent for 
Class Hormones and Metabolic Modulators I as this were true for all compounds present 
in that class. 
 
Figure 11. Chromatograms for Aminogluthemide Using Each of the Six Elution 
Solvent – ACN and MeOH pH 3, 7 and 10. 
 
Among pH 3, 7 and 10 for MeOH to choose the elution solvent that gives the most 
recovery, the area count of the peaks were calculated using TargetLynx©. It was used to 
calculate the area count for each compound using the six elution solvents. Then an average 
of the three injections per elution solvent was calculated. To determine the recovery a 
percentage of area count of elution solvent of the unextracted standard in 100% of that 
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solvent was calculated. The elution solvent that gave maximum recovery for all compounds 
in that class was selected. For each class a different elution solvent ended up giving the 
best results as shown in Table 21-27. 
 
Analyzing Extracted and Unextracted Spiked Urine and Water Samples Over a 
Period of one Month in Liquid Versus Solid Condition. 
In order to compare the stability of compounds in solid state versus liquid state, 
samples were loaded onto SPE cartridges and stored at 4° C and -20°C temperatures. This 
was termed as solid state as the compounds were separated from the matrix it was originally 
present in using solid phase extraction. To see if this technique improves the stability of 
the compound a comparison was made by storing the compounds in their liquid condition 
at the same temperatures for a period of one month and were analyzed at intervals of 1 
week with time points at 7 days (T1), 14 days (T2), 21 days (T3) and 28 days (T4). For 
solid state analysis the cartridges were loaded for all time points on T0 day and this was 
done in replicates of two. At 1 week intervals the compounds would be eluted from the 
cartridge and analyzed by LC MS method. For Liquid state the compounds would be loaded 
and eluted onto the cartridge on their respective time points and also analyzed using LC 
MS. The extraction was done on positive pressure vacuum manifold racks with 1 ml 
methanol used for conditioning followed by 1 ml MilliQ water used for equilibration. 
In order to carry out this comparison study water and urine samples were spiked with each 
class of compound being analyzed. Water samples served as a control, as urine is a more 
complex matrix than water but still is water based. Comparison with water samples help 
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understand matrix suppression effects that a complex matrix like urine can have on the 
compounds. 
The spiking concentration for each compound was determined and a mix for each 
class was prepared. Urine samples were acquired from four different individuals. All the 
urine samples were pooled together and mixed before spiking. Seven 50 ml tubes were 
measured and filled with 50 ml of urine. All seven tubes were spiked each containing 500 
µl of each of the class of compound. The same was done for MilliQ water samples. The 10 
ml of the 50 ml urine sample was then aliquot into 10 ml bottles for each of the seven 
classes and stored at 4°C to analyze the stability of the compounds in their liquid state. The 
same was repeated for the water sample. 15 ml of the of the remaining 40 ml were further 
divided in 3 ml and added to five 15 ml tubes and stored at -20°C. Each of the five tubes 
were labelled T1 to T4 for analyzing at each of the four time points in their liquid state at 
-20°C. Taking aliquots of 3 ml for each time point ensured the sample wasn’t thawed 
repeatedly for loading at each time point. Out of the 40 ml now the 25 ml that remained 
was used to load the cartridges for analysis in solid state for T1 to T4. All analysis was 
done for each of the seven classes and in replicates of two. The flowchart in Figure 12 
describes the spiking workflow explained above. 1 ml was loaded onto each cartridge and 
























Figure 12. Flowchart of Spiking Workflow for Solid Versus Liquid Extraction 
Process  
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This was done for +4°C and -20°C 
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3. RESULTS AND DISCUSSIONS 
3.1 MRM PROCEDURE 
     The compounds are prepared at three pH conditions to select the pH condition that gives 
the highest intensity for each compound. On picking the pH at which a compound gives 
the highest intensity, the collision energy is altered from 5 to 30 at that pH under MS2 scan  
until the precursor ion is completely fragmented and two product ions that have the highest 
intensity are selected. The spectrums below show the peak intensities at three different pH 
 (Figure 13) and the product ion fragments generated at varying collision energy values 
(Figure14).  
 
Figure 13. Spectrum of 17 Hydroxy-Progesterone Showing Peak Intensities at pH 3, 
7 and 10. 
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Figure 14. Spectrum of 17 Hydroxy-Progesterone Showing Fragments at Collision 
Energies 5 to 30. 
 
The two product ions showing the highest intensity are noted and the collision 
energy at which the product ion peak is the most intense is noted in the tables below. The 
precursor mass along with the product ion masses are fed into the system and are used to 
recognize these compounds when present in mixtures or matrices. 
The optimized values for the seven classes are displayed in separate multiple reaction 
monitoring (MRM) tables below (Tables 2-7). 

























Aminoglutethimide ESI+ 233.2 30 188.2 15 
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Hydrocortisone 
 































3.2 Method Development  
On analysis of all 36 methods for each class of compounds, Method 3 (Loading pH 
3 HLB Elution C18 pH 3 ACN) was selected for Class Macrolides and Class Quinolones. 
Method 11 (Loading pH 3 C18 Elution C18 pH 10 ACN) was selected for Class 2, Class 
Synthetic Cannabinoids and Class Hormones and Metabolic Modulators II. Method 14 
(Loading pH 7 C18 Elution C18 pH 10 ACN) was selected for Class Sulfas and Class 
Hormones and Metabolic Modulators II. In order to draw these conclusions, all the data for 
the class of compounds analyzed were put in tables and the methods that gave Gaussian 
peaks were highlighted in green, the ones that gave Non-Gaussian peaks were highlighted 











method 1 2 3 4 5 6 7 8 9
Aminoglutethimide H2O lead tail e7 e7 e7 e7 e7 tail 
Aminoglutethimide MeOH lead tail e7 e7 e7 e7 e7 blob
Aminoglutethimide ACN lead tail e7 e7 e7 e7 e7 tail 
Letrozole H2O e7 e7 e7 e7 e7 e7 e7 e7 e6
Letrozole MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Letrozole ACN e7 e7 e7 e7 e7 e7 e7 e7 e6
Levonorgestrel H2O e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen H2O e6 e5 e5 e5 e5 e5
Tamoxifen MeOH e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen ACN e7 e7 e7 e7 e7 e7 e7 e7
Cyclofenil  H2O e6 e7 e7 e6 e6 e6 e6 e6 e6
Cyclofenil  MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Cyclofenil  ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene H2O e7 e6 e6 e6 e4 e5 e6 e6
Clomiphene MeOH e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene ACN e8 e8 e8 e8 e8 e8 e8 e8
Toremifene H2O e6 e5 e5 e4 e5 e4
Toremifene MeOH e7 e7 e7 e7 e7 e7 e7 e7
Toremifene ACN e7 e7 e7 e7 e7 e7 e7 e7
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Table 9: Method Development for Hormones and Metabolic Modulators I Methods 
10 to 18 
 
 
method 10 11 12 13 14 15 16 17 18
Aminoglutethimide H2O e6 e6 e6 e6 e6 e6
Aminoglutethimide MeOH e6 e7 e6 e6 e6 e6
Aminoglutethimide ACN e6 e6 e6 e6 e6 e6
Letrozole H2O e7 e7 tail e7 e7 tail e7 e7 tail
Letrozole MeOH e7 e7 tail e7 e7 tail e7 e7 tail
Letrozole ACN e7 e7 tail e7 e7 tail e7 e7 tail
Levonorgestrel H2O e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen H2O e6 e5 e5 e6 e5
Tamoxifen MeOH e8 e8 e8 e8 e7 e7 e7 e7 e7
Tamoxifen ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Cyclofenil  H2O e6 e6 e7 e5 e7 e6 e5 e6 e6
Cyclofenil  MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Cyclofenil  ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene H2O e7 e6 e6 e6 e5 e6 e7 e7 e7
Clomiphene MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Toremifene H2O e6 e5 e5 e5 e4
Toremifene MeOH e7 e7 e7 e7 e5 e7 e7 e7 e7
Toremifene ACN e7 e7 e7 e7 e5 e7 e7 e7 e7
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Table 10: Method Development for Hormones and Metabolic Modulators I Methods 




method 19 20 21 22 23 24 25 26 27
Aminoglutethimide H2O e7 e7 tail e7 e7
Aminoglutethimide MeOH e7 e7 tail e7 e7
Aminoglutethimide ACN e7 e7 tail e7 e7
Letrozole H2O e7 e7 tail e7 e7 tail e7 e7 tail
Letrozole MeOH e7 e8 tail e7 e7 tail e7 e8 tail
Letrozole ACN e7 e7 tail e7 e7 tail e7 e7 tail
Levonorgestrel H2O e7 e7 tail e7 e7 tail e7 e7 tail
Levonorgestrel MeOH e7 e8 tail e7 e8 tail e7 e8 tail
Levonorgestrel ACN e7 e7 tail e7 e7 tail e7 e8 tail
Tamoxifen H2O e6 e5 e5 e4 e5 e5
Tamoxifen MeOH e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen ACN e7 e7 e7 e7 e7 e7 e7 e7
Cyclofenil  H2O e7 e7 tail e6 e6 tail e6 e6 tail
Cyclofenil  MeOH e8 e8 tail e8 e8 tail e8 e8 tail
Cyclofenil  ACN e8 e8 tail e8 e8 tail e8 e8 tail
Clomiphene H2O split shoulder shoulder split split split split split tail
Clomiphene MeOH split shoulder shoulder split split split split split tail
Clomiphene ACN split shoulder shoulder split split split split split tail
Toremifene H2O e6 e5 tail
Toremifene MeOH e7 e7 tail e6 e7 e7 e7 e7
Toremifene ACN e7 e7 tail e7 e7 e7 e7 e7
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Table 11: Method Development for Hormones and Metabolic Modulators I Methods 
28 to 36 
 
 
method 28 29 30 31 32 33 34 35 36
Aminoglutethimide H2O e6 e6 e6 tail e6 e6 tail
Aminoglutethimide MeOH e7 e7 e7 tail e6 e7 blob
Aminoglutethimide ACN e6 e6 tail e6 tail
Letrozole H2O e7 e7 e7 e7 e7 tail e7 e7 tail
Letrozole MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Letrozole ACN e7 e7 e7 e5 e7 tail e4 e7 tail
Levonorgestrel H2O e6 e7 e6 e6 e6 tail e6 e6 tail
Levonorgestrel MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Levonorgestrel ACN e7 e7 e7 e7 tail e7 tail
Tamoxifen H2O e5 e6 e5 e5 tail
Tamoxifen MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Tamoxifen ACN e7 e7 e7 e5 e7 tail e6 e7 tail
Cyclofenil  H2O e5 e6 e5 e5 tail e5 tail
Cyclofenil  MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Cyclofenil  ACN e7 e7 e7 e6 e7 tail e5 e7 tail
Clomiphene H2O e7 e7 e5 e5 e5 e6 e6 e6 e7
Clomiphene MeOH e8 e8 e8 e8 e8 tail e8 e8 e7
Clomiphene ACN e8 e8 e8 e6 e8 tail e7 e8 tail
Toremifene H2O e5 e5
Toremifene MeOH e6 e7 e6 e6 e6 e6 e6 e6 tail
Toremifene ACN e7 e6 e6 e6 e6 e5 e6 tail
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On analyzing the data only for each compound in organic solution is put on another 
table as shown in Table 12. The methods that give Gaussian peaks above an e5 signal for 
all compounds in that class are highlighted in green, the methods that cannot be selected 
are highlighted in blue. 
 After that the results for each class is put on a separate table, this final result as 
shown in Table 13 helps select the one best method for as many classes as possible. When 
many classes of compounds are being analyzed, it is most likely that more than one method 
is selected for all compounds. 








































































ACN PH 3 MeOH ACN MeOH ACN MeOH ACN MeOH ACN MeOH ACN MeOH ACN MeOH ACN
1- C8 pH 3 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 6
2- C18 pH 3 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 6
3- HLB pH 3 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 6
4- C8 pH 7 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 7
5- C18 pH 7 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 7
6- HLB pH 7 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 7
7- C8 pH 10 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 7
8- C18 pH 10 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e8 e8 e7 e7 7
9- HLB pH 10 e7 e6 e7 e7 e8 e8 3
ACN PH 10
10- C8 pH 3 e7 e7 e7 e7 e8 e8 e8 e8 e8 e8 e7 e7 6
11- C18 pH 3 e7 e7 e7 e7 e8 e8 e8 e8 e8 e8 e7 e7 6
12- HLB pH 3 e7 e7 e8 e8 e8 e8 e8 e8 e7 e7 5
13- C8 pH 7 e6 e6 e7 e7 e7 e7 e8 e5 e8 e8 e8 e8 e7 e7 7
14- C18 pH 7 e7 e6 e7 e7 e7 e7 e8 e7 e8 e8 e8 e8 e5 e5 7
15- HLB pH 7 e6 e6 e7 e7 e8 e6 e8 e8 e8 e8 e7 e7 6
16- C8 pH 10 e6 e6 e7 e7 e7 e7 e7 e8 e8 e8 e8 e8 e7 e7 7
17- C18 pH 10 e6 e6 e7 e7 e7 e7 e7 e8 e8 e8 e8 e8 e7 e7 7
18- HLB pH 10 e6 e6 e7 e7 e7 e8 e8 e8 e8 e8 e7 e7 6
MeOH PH 3
19- C8 pH 3 e7 e7 e7 e7 e7 e7 e8 e8 e7 e7 5
20- C18 pH 3 e8 e7 e8 e7 e7 e7 e8 e8 e7 e7 5
21- HLB pH 3 e7 e7 1
22- C8 pH 7 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e6 e7 6
23- C18 pH 7 e7 e7 e7 e7 e8 e7 e7 e7 e8 e8 e7 e7 6
24- HLB pH 7 e7 e7 e7 e7 2
25- C8 pH 10 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e7 e7 6
26- C18 pH 10 e7 e7 e8 e7 e8 e8 e7 e7 e8 e8 e7 e7 6
27- HLB pH 10
MeOH PH 10
28- C8 pH 3 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e6 e7 6
29- C18 pH 3 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e7 e6 6
30- HLB pH 3 e7 e6 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e6 e6 7
31- C8 pH 7 e7 e7 e5 e7 e7 e5 e7 e6 e8 e6 e6 7
32- C18 pH 7 e7 e6 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e6 e6 7
33- HLB pH 7 e6 e6 1
34- C8 pH 10 e6 e7 e4 e7 e7 e6 e7 e5 e8 e7 e6 e5 7
35- C18 pH 10 e7 e6 e7 e7 e7 e7 e7 e7 e7 e7 e8 e8 e6 e6 7
36- HLB pH 10 e7
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1- C8 pH 3 6 7 5 8 8 8
2- C18 pH 3 6 7 5 9 8 8 10
3- HLB pH 3 6 6 4 8 8 10
4- C8 pH 7 7 7 5 10 7 8 9
5- C18 pH 7 7 7 5 11 8 8 10 Hormones and Metabolic Modulators I - Method 14
6- HLB pH 7 7 6 4 7 8 10 Hormones and Metabolic Modulators II - Method 11
7- C8 pH 10 7 7 5 7 9 Synthetic Cannabinoids - Method 11
8- C18 pH 10 7 7 5 7 5 10 Sulfas - Method 14
9- HLB pH 10 3 3 4 3 8 10 Macrolides - Method 3
ACN PH 10 10 Quinolones - Method 3
10- C8 pH 3 6 6 5 11 6 Hormones - Method  11
11- C18 pH 3 6 7 5 11 7 10
12- HLB pH 3 5 6 3 8 7 10
13- C8 pH 7 7 6 5 11 7 10
14- C18 pH 7 7 6 5 12 7 10
15- HLB pH 7 6 6 3 4 7 10
16- C8 pH 10 7 6 5 7 10
17- C18 pH 10 7 6 5 2 7 10
18- HLB pH 10 6 6 3 7 10
MeOH PH 3
19- C8 pH 3 5 6 5 8 7 8
20- C18 pH 3 5 6 5 8 6 8 10
21- HLB pH 3 1 1 7 10
22- C8 pH 7 6 6 5 11 6 8
23- C18 pH 7 6 6 5 12 5 8 10
24- HLB pH 7 2 3 6 10
25- C8 pH 10 6 6 5 7
26- C18 pH 10 6 6 5 6 8 10
27- HLB pH 10 7 10
MeOH PH 10
28- C8 pH 3 6 7 5 11 8
29- C18 pH 3 6 7 5 11 8 10
30- HLB pH 3 7 7 8 6 10
31- C8 pH 7 7 7 5 10 7
32- C18 pH 7 7 7 5 9 7 10
33- HLB pH 7 1 2 4 7 10
34- C8 pH 10 7 7 5 8
35- C18 pH 10 7 7 5 2 7 10
36- HLB pH 10 7 10
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The chromatograms below are for all classes analyzed using their selected method with 
compounds diluted at 10 ppb in MeOH. (Figure 15 - 21). 
 
Figure 15. Chromatograms of Hormones and Metabolic Modulators I Compounds 
at 10ppb Using Method 14 
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Figure 16. Chromatograms of Sulfas Compounds at 10ppb Using Method 14 
 





Figure 18. Chromatograms of Hormones and Metabolic Modulators II Compounds 
at 10ppb Using Method 11 
 
 




Figure 20. Chromatograms of Quinolone Compounds at 10ppb Using Method 3 
 
 




3.3 Sample Preparation 
3.3.1 Selecting Spiking Concentration 
In order to select the spiking concentrations for each compound, each class of 
compound was analyzed at concentrations of 10, 1 and 0.1 ng/ml. The concentration at 
which a compound gave an e6 or e7 signal was chosen, in some cases an e5 signal was the 
highest intensity and that was accepted. The following Tables 14 - 20 show the area count 
of each compound at varying concentrations. As there is a 10-fold difference in 
concentration, there is a 10-fold difference in area count. In some cases, such as 
Clomiphene from Class Hormones and Metabolic Modulators I and 3b does not show a 10-
fold difference at 10 ng/ml, this is because the peak is saturated at an e8 signal. The data 
highlighted in yellow shows the discrepancies while the data highlighted in green shows a 
10-fold difference in area count as expected. 
 
Table 14: Area Count of Hormones and Metabolic Modulators I Compounds at 10, 1 




Hormones and  ACN ACN ACN MeOH MeOH MeOH
Metabolic Modulators I 0.1 1 10 0.1 1 10
Aminogluthemide 691.7 9620.4 96442.9 829.8 9565.4 105687.6
Letrozole 4550.2 44610.0 415835.4 5099.2 46642.6 441902.8
Levernogestrel 4686.3 46204.4 423204.9 5070.8 47276.8 435065.0
Tamoxifen 24352.8 222876.3 2033668.8 21516.5 208002.7 2071544.8
Cyclofenil 38324.2 381160.2 3528300.9 39744.8 378389.5 3665996.8
Clomiphene 285378.7 2461462.5 8329938.3 239403.9 2114105.4 8323861.8
Toremifene 4358.5 40720.2 383200.0 3897.8 34471.7 385791.3
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Table 15: Area Count of Sulfas Compounds at 10, 1 and 0.1 ng/ml 
 
 
Table 16: Area Count of Synthetic Cannabinoids Compounds at 10, 1 and 0.1 ng/ml 
 
 
Table 17: Area Count of Hormones and Metabolic Modulators II Compounds at 10, 




Sulfas ACN ACN ACN MeOH MeOH MeOH
0.1 1 10 0.1 1 10
sulfadiazine 866.5 4723.5 24801.9 396.3 1690.5 15935.4
sulfamethoxazole 42546.8 397852.1 3735081.3 40464.3 400904.5 3974110.2
flumequin 90127.2 715205.9 5282487.0 95771.8 958098.9 5756422.5
sulfisoxazole 32515.3 247373.3 1651192.0 30474.1 228857.9 2260554.8
sulfamethizole 28230.8 246646.1 2018232.2 25817.6 132479.2 1282186.0
tolbutamide 26130.7 161443.6 1364813.8 21293.6 142077.5 1445259.9
chlorpropamide 26130.7 161443.6 1364813.8 21293.6 142077.5 1445259.9
sulfamethizine 7266.2 57319.6 583116.1 6555.6 65147.0 638736.4
diacetooxyiodobenzene 39679.5 417932.8 3647325.3 42898.1 429156.2 4241419.4
chlorthalidone 1271.9 11243.8 108168.1 1146.2 11947.4 123648.9
indapamide 1144.5 10240.4 102263.6 1110.3 10792.5 107453.9
carbendazim 14911.6 93235.4 1243598.4 9586.0 90031.9 1198882.2
Synthetic Cannabinoids ACN ACN ACN MeOH MeOH MeOH
0.1 1 10 0.1 1 10
JWH-073 88565.5 895638.3 5715153.7 86740.1 894579.3 5714730.7
AB-PINACA 5444.1 58378.3 579101.6 5115.9 58141.2 574998.5
JWH-018 74409.9 768998.0 5304471.8 72729.7 742221.8 5319231.7
AM 2201 270868.1 2741864.7 7850861.2 268136.3 2789184.8 7912871.2
5F-PB-22 441654.9 4065074.2 8835814.3 435917.0 4097346.0 8894244.3
Hormones and  ACN ACN ACN MeOH MeOH MeOH
Metabolic Modulators II 0.1 1 10 0.1 1 10
Ralaxofene 54126.4 363912.6 3858774.7 66008.6 477467.3 5178906.8
Letrozole 7482.2 72809.1 680632.8 8312.5 67054.3 717788.9
Levernogestrel 6955.1 68820.8 655259.3 7493.8 63253.2 690323.0
Tamoxifen 27255.9 233574.2 2034038.8 26778.9 208174.9 2111912.8
Cyclofenil 38029.1 374874.9 3447671.7 39439.7 313035.0 3542255.3
Clomiphene 340550.8 2719565.8 8447079.5 323593.1 2393521.9 8543433.7
Toremifene 4877.7 41442.6 381457.8 4966.6 36731.4 393123.7
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Table 18: Area Count of Hormones Compounds at 10, 1 and 0.1 ng/ml 
 
 
Table 19: Area Count of Quinolones Compounds at 10, 1 and 0.1 ng/ml 
 
 
Table 20: Area Count of Macrolides Compounds at 10, 1 and 0.1 ng/ml 
 
Hormones ACN ACN ACN MeOH MeOH MeOH
0.1 1 10 0.1 1 10
Progesterone 16720.5 158346.8 1510180.0 17104.6 154758.9 1503733.0
17 Hydroxy Progesterone 6330.1 65328.3 625507.4 6793.0 64263.7 646003.0
Medroxyprogesterone 17299.7 157220.5 1564434.6 17219.1 156685.9 1557696.8
Cortisone 17299.7 157220.5 1564434.6 17219.1 156685.9 1557696.8
Hydrocortisone 4743.8 44529.4 431814.2 4643.3 44665.9 440736.1
6a methyl prednisolone 3947.1 38044.0 364682.8 3907.4 38971.8 376288.6
Medroxyprogesterone acetate 1838.9 17100.1 166468.9 1800.5 17185.4 169834.2
Cortisone-21-acetate 11330.4 108730.9 1028282.2 11703.5 106706.2 1009834.3
Triamicinolone acetonide 2912.2 29436.5 289483.5 2819.1 29246.3 298359.8
Triamicinolone diacetate 2300.0 21998.0 205769.0 2287.7 21476.8 202778.9
Quinolones ACN ACN ACN MeOH MeOH MeOH
0.1 1 10 0.1 1 10
Norfloxacin 52302.0 150428.6 1074693.9 43707.2 65533.6 721119.0
Enoxacin 35889.9 304411.8 2641005.8 23399.3 109633.8 2173663.7
Ciprofloxacin 7713.0 81016.3 851785.9 2724.5 24469.9 612093.5
Pefloxacin 14972.5 132340.3 1210385.3 12011.6 95291.3 1234047.9
Lomefloxacin 24842.8 257951.7 2704044.0 16684.1 163705.4 2526076.1
Nadifloxacin 41258.1 261190.7 2753740.4 47862.8 302952.8 2653331.4
Ofloxacin 52727.9 542214.7 4323117.8 36439.3 347925.6 4198687.6
Levofloxacin 53631.0 554560.0 4475315.7 38085.7 349395.9 4189961.3
Macrolides ACN ACN ACN MeOH MeOH MeOH
0.1 1 10 0.1 1 10
Erythromycin 39956.1 429965.6 4228705.8 42036.6 454981.9 4053039.8
Lincomycin 32453.1 308644.7 3218270.6 33068.9 297174.5 3169086.5
Clindamycin 77761.3 761887.2 5033210.2 85706.9 845467.5 4932220.0
Clarithromycin 91780.7 1034212.5 6345728.3 107245.1 1116057.7 6372941.8
Azithromycin 31639.8 376028.3 3723244.3 36980.1 399533.9 3679321.6
Dirithromycin 17689.3 144980.2 1740606.4 18198.7 200948.1 1963322.4
Roxithromycin 44831.4 465959.1 4514635.5 46663.3 481492.5 4464384.8
Spiramycin 4339.2 10291.1 481971.3 2092.0 46520.3 617791.1
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3.3.2 Selecting Elution Solvent for Each Class of Compounds 
Elution solvent was calculated based on recovery calculations, which is percentage 
of area count of peak of an extracted sample using a particular elution solvent by the area 
count of unextracted standard of that elution solvent. The following tables show the 
percentage recovery of each class of compound for each of the six elution solvents analyzed 
being MeOH and ACN pH 3, 7 and 10. The method that gave the maximum recovery for 
all compounds was selected and is highlighted in red. 
 
 





Table 22: Sulfas Elution Solvent Recovery Percentage Data 
 
Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
Aminogluthemide 50.1 94.5 100.7 81.0 97.5 98.9
Letrozole 87.5 85.8 84.6 84.4 87.3 86.7
Levernogestrel 86.1 80.8 86.0 79.7 80.4 66.5
Tamoxifen 63.5 34.1 17.6 74.9 20.6 13.2
Cyclofenil 47.5 42.3 38.8 33.4 28.4 0.5
Clomiphene 66.1 36.1 15.9 76.1 8.4 6.8
Toremifene 63.7 37.3 19.9 75.5 18.1 10.4
Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
sulfadiazine 102.2 105.2 27.6 74.1 86.2 10.9
sulfamethoxazole 100.1 99.8 7.9 93.0 105.8 7.1
flumequin 109.5 44.3 93.5 73.3 56.0 162.2
sulfisoxazole 112.8 110.5 5.8 93.7 101.5 17.3
sulfamethizole 98.1 101.7 8.8 90.3 103.0 9.3
tolbutamide 147.9 143.7 179.9 91.5 99.7 151.3
chlorpropamide 101.6 99.8 106.5 94.4 102.2 142.4
sulfamethizine 97.6 112.5 24.0 93.5 104.1 43.0
diacetooxyiodobenzene 97.0 53.9 90.6 97.7 108.8 109.4
chlorthalidone 102.0 55.2 91.1 95.4 106.9 99.7
indapamide 86.3 84.9 73.2 81.7 91.0 94.5
carbendazim 69.3 114.2 180.6 114.3 117.4 147.5
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Table 23: Synthetic Cannabinoids Elution Solvent Recovery Percentage Data 
 
 




Table 25: Hormones Elution Solvent Recovery Percentage Data 
 
 
The results for the Class Hormones in ACN showed peaks of low intensity having 
low signal to noise ratio, the area count for these peaks could not be determined. This shows 
ACN is not ideal to elute Class Hormones compounds. 
Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
JWH-073 63.0 66.2 60.6 9.8 10.1 5.4
AB-PINACA 95.6 87.9 94.8 65.6 48.2 44.2
JWH-018 48.8 48.6 51.2 6.5 6.6 3.5
AM 2201 69.6 72.7 73.4 11.1 11.7 6.3
5F-PB-22 90.6 83.6 87.3 34.2 27.0 14.6
Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
Ralaxofene 91.1 87.5 81.5 56.1 83.4 89.2
Letrozole 80.6 71.8 71.7 28.0 80.4 88.9
Levernogestrel 58.9 40.7 45.7 28.4 4.8 27.5
Tamoxifen 46.8 47.5 44.8 0.3 39.7 0.0
Cyclofenil 64.4 44.5 46.8 27.4 15.0 27.4
Clomiphene 58.4 43.6 49.8 27.0 29.2 41.0
Toremifene 105.8 0.2 10.2 46.6 12.8 76.6
Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
Progesterone NA NA NA 87.0 75.4 1.9
17 Hydroxy Progesterone NA NA NA 96.7 84.1 0.1
Medroxyprogesterone NA NA NA 97.0 85.2 0.3
Cortisone NA NA NA 250.3 239.7 0.5
Hydrocortisone NA NA NA 119.2 111.7 0.9
6a methyl prednisolone NA NA NA 105.3 94.8 0.4
Medroxyprogesterone acetate NA NA NA 87.6 76.2 0.2
Cortisone-21-acetate NA NA NA 71.4 59.5 1.3
Triamicinolone acetonide NA NA NA 99.3 88.3 0.1
Triamicinolone diacetate NA NA NA 85.8 64.8 0.0
57 
 
Table 26: Quinolones Elution Solvent Recovery Percentage Data 
 










Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
Norfloxacin 74.8 44.0 109.2 88.2 64.8 123.2
Enoxacin 81.3 13.9 80.4 88.0 37.1 116.9
Ciprofloxacin 85.7 16.0 79.5 146.7 65.3 248.6
Pefloxacin 62.0 24.7 72.1 40.4 39.3 86.4
Lomefloxacin 77.6 30.6 82.0 77.1 51.4 108.6
Nadifloxacin 93.7 42.2 87.3 79.5 46.3 86.7
Ofloxacin 78.0 30.6 82.6 77.5 51.2 108.7
Levofloxacin 78.0 30.6 82.6 77.5 51.2 108.7
Solvent ACN pH 3 ACN pH 7 ACN pH 10 MeOH pH 3 MeOH pH 7 MeOH pH 10
Erythromycin 2.3 53.6 66.0 1.8 72.3 80.4
Lincomycin 101.1 91.2 121.1 87.4 80.5 87.7
Clindamycin 74.3 65.5 70.0 88.9 79.9 81.7
Clarithromycin 74.9 52.7 63.5 92.1 69.6 79.3
Azithromycin 74.3 65.5 70.0 103.6 75.8 84.6
Dirithromycin 74.9 52.7 63.5 15.6 68.1 59.1
Roxithromycin 72.9 51.0 61.7 91.6 66.0 80.7
Spiramycin 41.3 29.0 35.4 63.7 62.0 67.0
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3.3.3 Analyzing Extracted and Unextracted Spiked urine and Water Samples Over a 
Period of one Month in Liquid Versus Solid Condition. 
The stability study workflow was designed in order to carry out comparison studies 
based on factors such as urine vs water spike; + 4 °C vs. -20 °C; solid vs liquid state and 
stability changes observed over a course of 4 weeks of unextracted standards. 
 
Urine vs. Water Spike 
On comparing the urine spike v/s the water spike data, for certain compounds 
intense peaks were observed in urine spike but not in the water spike, whereas in certain 
cases the same was observed in the water spike but not in the urine spike. This occurrence 
can be explained through compound suppression and enhancement effect that could occur 
due to interferences present in the matrix. As no wash step was introduced between loading 
and elution step during sample preparation, interferences in urine makes it a   slightly more 
complex matrix than water which could allow for the compound to be suppressed which is 
why the compound would be at a higher intensity in the water spike compared to the urine 
spike. Similarly, matrix enhancement effect could lead to certain compounds being present 
at very high intensities in urine spike compared to the water spike. Levofloxacin from 
Quinolones class showed enhancement effects. Table 28 shows the change in area count 
for Levofloxacin over 28 days. Sufisoxazole on the other hand shows suppression effect as 









7 14 21 28
H20 spike +4 °C A 273036.1 404237.8 465368.5 393401.2
H20 spike +4 °C B 472155.7 284580.9 379122.8 422345.0
H20 spike +4 °C A 54228.4 82759.5 43083.9 37090.7
H20 spike +4 °C B 51118.1 91666.4 32452.3 43606.3
H20 spike -20° C A 326531.1 425549.1 406899.4 505117.6
H20 spike -20° C B 310869.9 393082.2 465378.1 497225.3
H20 spike -20° C A 516855.7 611597.8 541805.0 523911.6
H20 spike -20° C B 527579.2 622033.1 542263.6 493392.7
Urine Spike  +4 °C A 2399934.9 2718966.4 2360501 2973505.1
Urine Spike  +4 °C B 2419329.1 2720549.5 2306328 2977582.7
Urine Spike  +4 °C A 2513663.3 2817030.0 2442487 3153811.6
Urine Spike  +4 °C B 2620636.7 2930804.8 2457382 3006217.6
Urine Spike  -20° C A 2475274.9 2055818.8 2282310 2743318.5
Urine Spike  -20° C B 2440115.4 2072775.3 2208983 2719787.2
Urine Spike  -20° C A 2314621.0 10830.7 2231959 3016969.3











Figure 22. Graph Showing Stability Changes in Terms of Area Count for 
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7 14 21 28
H20 spike +4 °C A 125797.3 64126.6 179570.0 52349.3
H20 spike +4 °C B 90292.9 51392.3 192481.3 51504.1
H20 spike +4 °C A 132670.7 97334.9 229061.9 71246.3
H20 spike +4 °C B 131732.0 97109.5 228839.2 72776.4
H20 spike -20° C A 143263.1 96585.7 212547.6 57291.9
H20 spike -20° C B 143093.2 97775.3 215944.5 69660.4
H20 spike -20° C A 135580.3 105555.5 228660.4 77170.9
H20 spike -20° C B 139237.8 104371.8 228010.6 76505.4
Urine Spike  +4 °C A 859.3 1184.5 5975.6 1748.5
Urine Spike  +4 °C B 1088.4 1174.1 5687.3 1775.3
Urine Spike  +4 °C A 849.0 1437.9 6308.9 1997.0
Urine Spike  +4 °C B 932.6 1400.6 6144.9 1350.7
Urine Spike  -20° C A 1107.1 1152.3 6210.9 1715.1
Urine Spike  -20° C B 779.7 1479.3 5864.0 1895.5
Urine Spike  -20° C A 996.1 1329.7 5776.4 1459.3











Figure 23. Graph Showing Stability Changes in Terms of Area Count for 
Sulfisoxazole Under Various Conditions for 28 Days 
 
+4°C vs. -20°C 
When data was analyzed to compare changes in area count for +4°C and -20°C, no 
significant difference was found for 48 samples between the two temperatures. Although 
it is expected that at -20°C the degradation effects should be lesser, not all compounds 
support this theory. This might suggest that the slight decline in area count that was 
observed might have occurred due to other factors such as oxidation or photolysis which 
have not been analyzed in this study. Letrozole is one such compound that showed no 
significant difference in area count based on temperature as shown in Table 30 whereas 
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Table 30:  Stability Changes with Respect to Area Count for Letrozole Over 28 Days 
 
 
7 14 21 28
H20 spike +4 °C A 273242.0 255855.1 244193.8 90580.7
H20 spike +4 °C B 309481.9 255716.4 250350.4 90983.9
H20 spike +4 °C A 292365.3 244932.2 226745.8 69994.0
H20 spike +4 °C B 329686.4 220544.0 225939.0 65395.3
H20 spike -20° C A 401014.8 258845.0 217366.2 76908.5
H20 spike -20° C B 376604.9 266273.1 234321.3 77583.0
H20 spike -20° C A 355233.5 239201.0 235248.3 73019.4
H20 spike -20° C B 341613.3 231874.6 225218.1 81342.0
Urine Spike  +4 °C A 97083.7 78907.5 38923.0 30229.8
Urine Spike  +4 °C B 98031.7 77845.1 38022.2 26507.7
Urine Spike  +4 °C A 105799.3 83661.5 48534.1 41567.5
Urine Spike  +4 °C B 101718.5 82830.3 48298.5 36480.3
Urine Spike  -20° C A 94398.5 81243.2 41221.2 34126.3
Urine Spike  -20° C B 89835.1 77472.9 41221.2 37955.0
Urine Spike  -20° C A 109774.2 95678.1 47269.1 41969.6











Figure 24. Graph Showing Stability Changes in Terms of Area Count for Letrozole 
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7 14 21 28
H20 spike +4 °C A 37462.1 32652.5 31898.8 30828.8
H20 spike +4 °C B 44534.1 24949.0 26876.6 32191.8
H20 spike +4 °C A 8870.0 12589.9 5794.4 7104.1
H20 spike +4 °C B 8081.4 14486.4 5841.6 6311.0
H20 spike -20° C A 55369.2 70048.5 40353.0 53062.8
H20 spike -20° C B 50728.0 63038.2 40874.7 49024.1
H20 spike -20° C A 88346.3 105316.9 82695.5 84800.5
H20 spike -20° C B 92611.0 103218.7 82214.0 81972.3
Urine Spike  +4 °C A 11547.9 17256.6 15617.8 30152.3
Urine Spike  +4 °C B 12922.8 20485.9 15213.1 30568.2
Urine Spike  +4 °C A 17280.8 24716.7 25614.1 43191.4
Urine Spike  +4 °C B 18400.7 23239.2 24286.1 42848.5
Urine Spike  -20° C A 14062.5 13824.7 15869.2 33034.8
Urine Spike  -20° C B 14981.0 11243.0 20095.5 32161.7
Urine Spike  -20° C A 19858.9 429.2 18017.8 38603.9











Figure 25. Graph Showing Stability Changes in Terms of Area Count for 
Ciprofloxacin Under Various Conditions for 28 Days 
 
Solid vs. Liquid  
There is not much significant difference in solid state versus liquid state in terms 
of stability of the compounds analyzed. This shows that loading onto solid state as opposed 
to keeping it in its liquid state does not affect the stability of the compound and can be used 
as an alternative method for storage and transportation. If stability study was carried out 
for longer than 28 days, it could be determined if difference is significant or not between 
solid state and liquid state long term storage. Levernogestrel shows no significant 
difference between solid versus liquid state whereas, Cortisone-21-acetate shows 
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7 14 21 28
H20 spike +4 °C A 27879.0 37505.6 32826.2 23371.0
H20 spike +4 °C B 29750.0 36321.7 32805.7 22853.3
H20 spike +4 °C A 27500.9 31969.5 19352.7 11783.3
H20 spike +4 °C B 26905.2 29258.9 20291.5 11229.6
H20 spike -20° C A 38197.5 31441.3 24304.5 12798.7
H20 spike -20° C B 34951.6 32977.7 27598.4 11933.2
H20 spike -20° C A 26021.6 23863.4 18826.0 8067.3
H20 spike -20° C B 25362.4 21984.4 18591.7 9158.4
Urine Spike  +4 °C A 44038.2 40067.1 32852.2 16580.6
Urine Spike  +4 °C B 45618.1 41232.1 32569.9 10964.8
Urine Spike  +4 °C A 50029.6 42717.4 35683.2 13935.5
Urine Spike  +4 °C B 47751.1 40677.7 34815.8 11238.7
Urine Spike  -20° C A 45579.5 44552.4 34784.3 13567.6
Urine Spike  -20° C B 44454.9 41938.8 33737.6 13533.4
Urine Spike  -20° C A 52809.8 48748.7 34036.4 12822.7











Figure 26. Graph Showing Stability Changes in Terms of Area Count for 
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Table 33:  Stability Changes with Respect to Area Count for Cortisone-21-Acetate 
Over 28 Days 
 
 
7 14 21 28
H20 spike +4 °C A 327487.4 NA 202505.2 331678.4
H20 spike +4 °C B 359005.7 NA 203569.7 313868.8
H20 spike +4 °C A 125499.6 NA 98793.4 149606.6
H20 spike +4 °C B 134119.5 95426.6 102788.5 126776.1
H20 spike -20° C A NA NA 195257.5 249048.2
H20 spike -20° C B 624685.9 NA 191572.1 263863.4
H20 spike -20° C A 262231.9 191762.2 155730.7 199734.6
H20 spike -20° C B 235801.6 172533.3 165091.4 218343.8
Urine Spike  +4 °C A 211161.0 NA 100622.1 182644.8
Urine Spike  +4 °C B 247014.1 NA 56033.0 164301.6
Urine Spike  +4 °C A 233795.8 NA 80522.2 169403.2
Urine Spike  +4 °C B 229265.7 157874.4 95935.3 174872.1
Urine Spike  -20° C A 227542.7 NA 108004.0 129069.5
Urine Spike  -20° C B 205313.4 76593.5 204802.8 219398.4
Urine Spike  -20° C A NA 161824.5 190910.0 188888.1











Figure 27. Graph Showing Stability Changes in Terms of Area Count for Cortisone -
21-Acetate Under Various Conditions for 28 Days 
 
Analyzing Stability Over Period of 28 Days 
On comparing area count for compounds over 28 days, certain compounds showed 
significant difference but other compounds did not show a significant difference.  The drop 
could occur due to various factors that cause degradation such as oxidation, enzyme 
degradation, hydrolysis. Clindamycin shows consistent data over a period of 4 weeks but 
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7 14 21 28
H20 spike +4 °C A 98889.9 103545.1 28172.5 33389.1
H20 spike +4 °C B 116839.8 111841.8 31188.1 29494.1
H20 spike +4 °C A 132349.4 136324.3 27541.4 38329.6
H20 spike +4 °C B 145051.1 119383.2 40152.4 35936.8
H20 spike -20° C A 163664.4 134801.8 40517.3 38762.1
H20 spike -20° C B 152957.6 141812.7 43008.1 36029.6
H20 spike -20° C A 162670.2 134627.8 42282.6 36665.2
H20 spike -20° C B 159410.2 128665.4 46240.6 34504.4
Urine Spike  +4 °C A 12774.1 8798.8 3379.8 3916.6
Urine Spike  +4 °C B 12466.0 9420.0 3119.2 4009.0
Urine Spike  +4 °C A 15573.4 10508.5 4004.1 4867.8
Urine Spike  +4 °C B 15755.1 10185.0 4222.4 5039.4
Urine Spike  -20° C A 12633.1 8751.9 3237.5 4181.7
Urine Spike  -20° C B 12384.1 8357.4 3259.9 3961.8
Urine Spike  -20° C A 15694.2 10795.2 3681.5 4689.6











Figure 28. Graph Showing Stability Changes in Terms of Area Count for 
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7 14 21 28
H20 spike +4 °C A 480421.9 218.3563 379664.2 479041.6
H20 spike +4 °C B 556208.5 39.20533 418590.3 421705.8
H20 spike +4 °C A 556208.5 18.70667 584336.8 554923.2
H20 spike +4 °C B 546570.3 493742.1 528422 566408.6
H20 spike -20° C A 572213.1 244.7013 497634.8 624141.1
H20 spike -20° C B 535959.2 454504.6 563126.8 716642.2
H20 spike -20° C A 945801.8 848921.5 705486.1 702340.6
H20 spike -20° C B 958841.7 679687.8 639767.1 702122.2
Urine Spike  +4 °C A 112637.6 304.0125 99175.24 102159.3
Urine Spike  +4 °C B 120054.1 82.04033 100873.3 106238.5
Urine Spike  +4 °C A 176942.7 129602.3 191022.9 198803.2
Urine Spike  +4 °C B 175116.8 119572.8 185418.5 209048.7
Urine Spike  -20° C A 143065.4 85.3315 108735.7 114352.8
Urine Spike  -20° C B 128924.7 94724.17 99994.95 118830.4
Urine Spike  -20° C A 272518.5 184174.6 197336.7 203938.4











Figure 29. Graph Showing Stability Changes in Terms of Area Count for 
Clindamycin Under Various Conditions for 28 Days 
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Most compounds showed enhancement or suppression effect in urine spike 
compared to water spike and as discussed before. It is due to lack of a wash step between 
loading and elution during sample preparation. 27 compounds showed suppression effect, 
13 showed enhancement effect and remaining 11 showed no matrix effect.   
 Class Sulfas show a pattern of consistent data until 21 days however a sudden 
degradation is seen in week 4 data. Also these class of compounds show suppression effect 
in urine spike and these compounds are affected more by components of urine than other 
compounds are.          
 Class Quinolones show higher area count for -20°C than +4°C. These compounds 
support the theory that storage at freezing temperature can help maintain compound 
stability. It is probably because these compounds are more temperature sensitive compared 
to other compounds. Five compounds- Norfloxacin, Enoxacin, Ciprofloxacin, Pefloxacin 
and Lomefloxacin in this class showed this pattern.     
 It cannot be conclusively determined based on current data if solid phase extraction 
can help improve or maintain the stability of compounds but the current data does show 
that storage using SPE has no negative impact on stability of compounds and that there is 
scope for further study regarding long term storage of these compounds using SPE. Six 
Quninolones- Norfloxacin, Enoxacin, Ciprofloxacin, Pefloxacin, Lomefloxacin and 
Nadifloxacin showed that for +4°C water spike, the solid state shows higher area count 
than liquid state but for -20°C water spike liquid state shows higher area count than solid 
state. Cortisone-21 acetate and Triamicinolone diacetate from class Hormones showed that 
solid state shows higher area count for +4°C but the data for -20°C water spike is consistent 
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in terms of solid versus liquid state. Lincomycin +4°C and -20°C water spike show that 
solid state shows lower area count than that of liquid state.                                                    
 Ralaxofene shows sudden enhancement after week 3 onwards. Cyclofenil shows a 
sudden enhancement during week 4 data. These are a few anomalies that were observed 
from the general pattern that was observed across most compounds.    
 Around 25 compounds showed inconsistent stability and 26 compounds showed 
consistent stability over 28 days. These inconsistencies in stability data could be due to the 
various other factors that affect stability that were not analyzed in this study such as pH, 




The objective of this study was to compare the stability of pharmaceuticals and 
hormones over various different factors such as temperature- +4 °C and -20 °C; storage 
state- liquid or solid and in water and urine samples, over a period of 28 days. Out of 51 
compounds analyzed, only 42 showed no significant difference in degradation between 
solid versus liquid state, 40 compounds showed a significant difference in area count while 
comparing urine spike versus water spike which is due to lack of sample clean up that could 
be countered by adding a wash step and only 46 compounds showed no significant 
difference in stability when kept at -20 °C as compared to +4 °C.  
Through this study, conclusions can be drawn that using SPE cartridges could be 
an alternative to storing in liquid conditions as there is no significant loss of compound 
seen over a period of one month between these two storage methods. However, if this study 
were to be extended for period longer than 28 days, it would answer the question if SPE 
cartridges do offer an advantage over liquid storing conditions.  
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6. FUTURE CONSIDERATIONS 
Due to time restrictions, the stability study could not be carried out for a period 
longer than a month. Increasing number of time points for a period of 2 to 3 months more 
could give data on long term stability. Also using biological matrices other than urine such 
as blood plasma or even saliva.  
Some compounds from classes such as Meldonium, Prednisolone, UR-144, Methyl 
prednisolone acetate and few more compounds had to be dropped out as their peak shapes 
showed distortion over a period of time. Further research into these compounds could 
explain whether the distortion was due to stability changes or interferences from other 
compounds or even due to adsorption or solubility issues. Discrepancies in peak shape of 
Aminogluthemide and solubility issues of Dirithromycin in water spike should also be 
further researched. 
When analyzing the stability of these compounds in urine, some compounds were 
unable to be detected to due matrix suppression effects and adding wash steps during 
extraction could further reduce these suppression effects. Some compounds also gave low 
recovery, so different elution solvents could be experimented with during extraction to 
improve recovery. 
Analysis was carried out only using HLB cartridges. A comparison study using 
HLB Prime cartridges could provide additional data on whether that improves extraction 
processes and recovery of compounds as opposed to using HLB cartridges. 
An additional study based on unextracted standards could be carried out to see if 
these inconsistencies can be attributed to the instrument. Some compounds showed 
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some discrepancies that need to be further looked into, Aminogluthemide showed broader 
peak than usual over a period of time and Dirithromycin probably has solubility issues in 
water as was seen during method development. Spiramycin and Cyclofenil showed low 
signal intensity and needs to be analyzed at a higher concentration than 1.0 and 0.1 ng/ml 
respectively 
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APPENDIX A:   
Table A: Method Development for Hormones and Metabolic Modulators II Methods 




method 1 2 3 4 5 6 7 8 9
Letrozole H2O e7 e7 e7 e7 e7 e7 e7 e7 e6
Letrozole MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Letrozole ACN e7 e7 e7 e7 e7 e7 e7 e7 e6
Levonorgestrel H2O e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen H2O e6 e5 e5 e5 e5 e5
Tamoxifen MeOH e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen ACN e7 e7 e7 e7 e7 e7 e7 e7
Cyclofenil  H2O e6 e7 e7 e6 e6 e6 e6 e6 e6
Cyclofenil  MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Cyclofenil  ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene H2O e7 e6 e6 e6 e4 e5 e6 e6
Clomiphene MeOH e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene ACN e8 e8 e8 e8 e8 e8 e8 e8
Toremifene H2O e6 e5 e5 e4 e5 e4
Toremifene MeOH e7 e7 e7 e7 e7 e7 e7 e7
Toremifene ACN e7 e7 e7 e7 e7 e7 e7 e7
Raloxifene H2O e7 e6 tail e5 e4 tail e8 e7
Raloxifene MeOH e8 e8 tail e8 e8 tail e8 e8
Raloxifene ACN e8 e8 tail e8 e8 tail e8 e8
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Table B: Method Development for Hormones and Metabolic Modulators II Methods 
10 to 18 
 
 
method 10 11 12 13 14 15 16 17 18
Letrozole H2O e7 e7 tail e7 e7 tail e7 e7 tail
Letrozole MeOH e7 e7 tail e7 e7 tail e7 e7 tail
Letrozole ACN e7 e7 tail e7 e7 tail e7 e7 tail
Levonorgestrel H2O e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Levonorgestrel ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen H2O e6 e5 e5 e6 e5
Tamoxifen MeOH e8 e8 e8 e8 e7 e7 e7 e7 e7
Tamoxifen ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Cyclofenil  H2O e6 e6 e7 e5 e7 e6 e5 e6 e6
Cyclofenil  MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Cyclofenil  ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene H2O e7 e6 e6 e6 e5 e6 e7 e7 e7
Clomiphene MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Clomiphene ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Toremifene H2O e6 e5 e5 e5 e4
Toremifene MeOH e7 e7 e7 e7 e5 e7 e7 e7 e7
Toremifene ACN e7 e7 e7 e7 e5 e7 e7 e7 e7
Raloxifene H2O lead e6 tail tail tail tail
Raloxifene MeOH lead e8 tail tail tail tail tail tail tail
Raloxifene ACN lead e8 tail tail tail tail tail tail tail
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Table C: Method Development for Hormones and Metabolic Modulators II Methods 





method 19 20 21 22 23 24 25 26 27
Letrozole H2O e7 e7 tail e7 e7 tail e7 e7 tail
Letrozole MeOH e7 e8 tail e7 e7 tail e7 e8 tail
Letrozole ACN e7 e7 tail e7 e7 tail e7 e7 tail
Levonorgestrel H2O e7 e7 tail e7 e7 tail e7 e7 tail
Levonorgestrel MeOH e7 e8 tail e7 e8 tail e7 e8 tail
Levonorgestrel ACN e7 e7 tail e7 e7 tail e7 e8 tail
Tamoxifen H2O e6 e5 e5 e4 e5 e5
Tamoxifen MeOH e7 e7 e7 e7 e7 e7 e7 e7
Tamoxifen ACN e7 e7 e7 e7 e7 e7 e7 e7
Cyclofenil  H2O e7 e7 tail e6 e6 tail e6 e6 tail
Cyclofenil  MeOH e8 e8 tail e8 e8 tail e8 e8 tail
Cyclofenil  ACN e8 e8 tail e8 e8 tail e8 e8 tail
Clomiphene H2O split shoulder shoulder split split split split split tail
Clomiphene MeOH split shoulder shoulder split split split split split tail
Clomiphene ACN split shoulder shoulder split split split split split tail
Toremifene H2O e6 e5 tail
Toremifene MeOH e7 e7 tail e6 e7 e7 e7 e7
Toremifene ACN e7 e7 tail e7 e7 e7 e7 e7
Raloxifene H2O e7 e7 tail e4 e4 e5 e8 e8
Raloxifene MeOH e8 e8 tail e8 e8 e8 e8 e8
Raloxifene ACN e8 e8 tail e8 e8 e8 e8 e8
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method 28 29 30 31 32 33 34 35 36
Letrozole H2O e7 e7 e7 e7 e7 tail e7 e7 tail
Letrozole MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Letrozole ACN e7 e7 e7 e5 e7 tail e4 e7 tail
Levonorgestrel H2O e6 e7 e6 e6 e6 tail e6 e6 tail
Levonorgestrel MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Levonorgestrel ACN e7 e7 e7 e7 tail e7 tail
Tamoxifen H2O e5 e6 e5 e5 tail
Tamoxifen MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Tamoxifen ACN e7 e7 e7 e5 e7 tail e6 e7 tail
Cyclofenil  H2O e5 e6 e5 e5 tail e5 tail
Cyclofenil  MeOH e7 e7 e7 e7 e7 tail e7 e7 tail
Cyclofenil  ACN e7 e7 e7 e6 e7 tail e5 e7 tail
Clomiphene H2O e7 e7 e5 e5 e5 e6 e6 e6 e7
Clomiphene MeOH e8 e8 e8 e8 e8 tail e8 e8 e7
Clomiphene ACN e8 e8 e8 e6 e8 tail e7 e8 tail
Toremifene H2O e5 e5
Toremifene MeOH e6 e7 e6 e6 e6 e6 e6 e6 tail
Toremifene ACN e7 e6 e6 e6 e6 e5 e6 tail
Raloxifene H2O e7 e7 e4 e4 e4 e5 e7 e7 tail
Raloxifene MeOH e8 e8 e8 e8 e8 e8 e8 e8 tail
Raloxifene ACN e8 e8 e8 e6 e8 e8 e5 e8 tail
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method 1 2 3 4 5 6 7 8 9
JWH-073 H20 e7 e6 tail e6 e5 tail e7 e5 tail
JWH-073 MeOH e7 e7 tail e8 e6 tail e8 e8 tail
JWH-073 ACN e8 e8 tail e8 e8 tail e8 e8 tail
AB-PINACA H20 e6 e7 e6 e7 e6 e6 e7 e7 e7
AB-PINACA MeOH e7 e7 e7 e7 e5 e7 e7 e7 e7
AB-PINACA ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
JWH-018 H20 e6 e5 e5 e6 e5 e5 e7 e5 e5
JWH-018 MeOH e6 e6 e8 e8 e7 e8 e8 e8 e8
JWH-018 ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
AM2201  H20 e7 e6 e6 e7 e5 e6 e8 e6 e6
AM2201 MeOH e8 e7 e8 e8 e6 e8 e8 e8 e8
AM2201 ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
5F-PB-22 H20 e8 e8 e8 e8 e7 e7 e8 e7 e7
5F-PB-22 MeOH e8 e8 e8 e8 e6 e8 e8 e8 e8
5F-PB-22 ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
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method 10 11 12 13 14 15 16 17 18
JWH-073 H20 e7 e6 e6 e7 e6 e5 e7 e5 e5
JWH-073 MeOH e7 e8 e8 e7 e8 e8 e8 e8 e8
JWH-073 ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
AB-PINACA H20 e6 e7 e7 e6 e7 e7 e6 e7 e7
AB-PINACA MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
AB-PINACA ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
JWH-018 H20 e6 e5 tail e6 e6 tail e6 e6 tail
JWH-018 MeOH e6 e8 e8 e7 e8 e8 e7 e8 e8
JWH-018 ACN e8 e8 tail e8 e8 tail e8 e8 tail
AM2201  H20 e7 e7 tail e7 e6 tail e7 e6 tail
AM2201 MeOH e8 e8 tail e8 e8 tail e8 e8 tail
AM2201 ACN e8 e8 tail e8 e8 tail e8 e8 tail
5F-PB-22 H20 e8 e8 tail e8 e7 tail e8 e7 tail
5F-PB-22 MeOH e8 e8 tail e8 e8 tail e8 e8 tail
5F-PB-22 ACN e8 e8 tail e8 e8 tail e8 e8 tail
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method 19 20 21 22 23 24 25 26 27
JWH-073 H20 e7 e7 tail e6 e6 tail e7 e6 tail
JWH-073 MeOH e7 e8 tail e8 e8 tail e8 e8 tail
JWH-073 ACN e8 e8 tail e8 e8 tail e8 e8 tail
AB-PINACA H20 e7 e7 tail e7 e7 tail e7 e7 tail
AB-PINACA MeOH e7 e7 tail e7 e7 tail e7 e7 tail
AB-PINACA ACN e7 e7 tail e6 e7 tail e7 e7 tail
JWH-018 H20 e6 e6 tail e6 e5 tail e6 e5 tail
JWH-018 MeOH e7 e7 tail e8 e8 tail e8 e8 tail
JWH-018 ACN e8 e8 tail e8 e8 tail e8 e8 tail
AM2201  H20 e7 e7 tail e7 e7 tail e7 e7 tail
AM2201 MeOH e8 e8 tail e8 e8 tail e8 e8 tail
AM2201 ACN e8 e8 tail e8 e8 tail e8 e8 tail
5F-PB-22 H20 e8 e8 tail e8 e8 tail e8 e8 tail
5F-PB-22 MeOH e8 e8 tail e8 e8 tail e8 e8 tail
5F-PB-22 ACN e8 e8 tail e8 e8 tail e8 e8 tail
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method 28 29 30 31 32 33 34 35 36
JWH-073 H20 e6 e6 tail e5 e5 tail e5 e5 tail
JWH-073 MeOH e7 e8 tail e6 e8 tail e7 e8 tail
JWH-073 ACN e7 e8 tail e7 e8 tail e7 e8 tail
AB-PINACA H20 e6 e6 tail e6 e6 tail e6 e6 tail
AB-PINACA MeOH e6 e6 tail e6 e6 tail e6 e6 tail
AB-PINACA ACN e5 e6 tail e5 e6 tail e5 e6 tail
JWH-018 H20 e5 e5 tail e5 e4 tail e5 e5 tail
JWH-018 MeOH e6 e8 tail e5 e7 tail e6 e8 tail
JWH-018 ACN e7 e8 tail e7 e8 tail e7 e8 tail
AM2201  H20 e6 e6 tail e6 e6 tail e6 e6 tail
AM2201 MeOH e7 e8 tail e7 e8 tail e7 e8 tail
AM2201 ACN e7 e8 tail e7 e8 tail e7 e8 tail
5F-PB-22 H20 e8 e8 tail e8 e7 tail e8 e8 tail
5F-PB-22 MeOH e8 e8 tail e8 e8 tail e8 e8 tail
5F-PB-22 ACN e7 e8 tail e7 e8 tail e7 e8 tail
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method 1 2 3 4 5 6 7 8 9
carbendazim H2O broad e6 tail broad e6 tail lead
carbendazim MeOH broad e6 tail split e7 tail lead
carbendazim ACN broad e6 tail lead e7 e7 tail lead
sulfadiazine H2O blob broad blob broad split blob
sulfadiazine MeOH blob broad blob shoulder split blob
sulfadiazine ACN blob broad blob split split blob
Sulfamethoxazole H2O e7 e7 blob e7 e7 tail
Sulfamethoxazole MeOH e7 e7 blob e7 e7 tail
Sulfamethoxazole ACN e7 e7 blob e7 e7 tail
Flumequin H2O e8 e8 tail e8 e8 tail
Flumequin MeOH e8 e8 tail e8 e8 tail
Flumequin ACN e8 e8 tail e8 e8 tail
Sulfisoxazole  H2O e7 e7 blob e7 e7 tail
Sulfisoxazole  MeOH e7 e7 blob e7 e7 tail
Sulfisoxazole  ACN e7 e6 blob e7 e7 tail
Sulfamethizole H2O lead lead blob e7 e7 tail tail
Sulfamethizole MeOH lead lead blob e7 e7 tail tail
Sulfamethizole ACN lead lead blob e7 e7 tail tail
tolbutamide H2O e8 e8 tail e8 e8 tail tail
tolbutamide MeOH e8 e8 tail e8 e8 tail tail
tolbutamide ACN e8 e8 tail e8 e8 tail tail
chlorpropamide H2O e7 e7 tail e7 e7 tail
chlorpropamide MeOH e8 e7 tail e8 e7 tail
chlorpropamide ACN e7 e7 tail e8 e7 tail
sulfamethazine H2O lead lead blob e8 e8 tail blob 
sulfamethazine MeOH lead lead blob e8 e8 tail tail
sulfamethazine ACN lead lead blob e7 e7 tail  shoulder
(Diacetoxyiodo)benzene H2O e6 e7 tail e6 e7 tail
(Diacetoxyiodo)benzene MeOH e6 e7 tail e7 e7 tail
(Diacetoxyiodo)benzene ACN e6 e7 tail e6 e7 tail
chlorthalidone H20 e6 e7 tail e6 e7 tail
chlorthalidone  MeOH e6 e7 tail e7 e7 tail
chlorthalidone ACN e6 e7 tail e6 e7 tail
Indapamide H2O e7 e7 tail e7 e7 tail
Indapamide MeOH e8 e7 tail e8 e7 tail
Indapamide ACN e7 e7 tail e7 e7 tail
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method 10 11 12 13 14 15 16 17 18
carbendazim H2O blob lead shoulder e7 tail lead
carbendazim MeOH shoulder lead shoulder e8 tail e7
carbendazim ACN shoulder lead shoulder e8 tail e7
sulfadiazine H2O e5 e6 e8 e6 e6 e7
sulfadiazine MeOH e5 e5 e8 e4 e6 e4
sulfadiazine ACN e5 e6 e8
Sulfamethoxazole H2O e8 e8 e8 e8 e7 e7 tail
Sulfamethoxazole MeOH e8 e8 e8 e6 e7 e4 tail
Sulfamethoxazole ACN e8 e8 e8 e5 e5 e4 tail
Flumequin H2O e8 e8 e8 e8 e8 e6
Flumequin MeOH e8 e8 e8 e7 e8 e6
Flumequin ACN e8 e8 e8 e7 e8 e6
Sulfisoxazole  H2O e8 e7 e8 e8 e7 e7
Sulfisoxazole  MeOH e8 e8 e8 e6 e7 e4
Sulfisoxazole  ACN e8 e8 e8 e5 e5 e4
Sulfamethizole H2O e7 e6 e8 e8 e7 e7
Sulfamethizole MeOH e7 e6 e8 e6 e6 e4
Sulfamethizole ACN e6 e6 e8 e5 e5 e4
tolbutamide H2O e7 e8 e8 e7 e7 e7 e7
tolbutamide MeOH e8 e8 e8 e6 e8 e5 e7
tolbutamide ACN e7 e8 e8 e5 e8 e5 e7
chlorpropamide H2O e7 e7 e8 e7 e7 e7 e7
chlorpropamide MeOH e7 e7 e8 e6 e7 e5 e7
chlorpropamide ACN e7 e7 e8 e5 e6 e5 e6
sulfamethazine H2O e6 e6 e8 e8 e8 e8 e4
sulfamethazine MeOH e6 e6 e8 e6 e8 e5 e4
sulfamethazine ACN e6 e6 e8 e5 e7 e5 e6
(Diacetoxyiodo)benzene H2O e7 e7 tail e7 e7 tail e4
(Diacetoxyiodo)benzene MeOH e7 e7 tail e5 e7 e4
(Diacetoxyiodo)benzene ACN e7 e7 tail
chlorthalidone H20 e7 e7 tail e7 e7 tail
chlorthalidone  MeOH e7 e7 tail e5 e7
chlorthalidone ACN e7 e7 tail
Indapamide H2O e7 e7 tail e7 e7 tail
Indapamide MeOH e7 e7 tail e6 e7 tail
Indapamide ACN e7 e6 tail e5 e6 tail
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method 19 20 21 22 23 24 25 26 27
carbendazim H2O broad tail blob broad broad tail
carbendazim MeOH broad tail blob split e7 tail
carbendazim ACN broad tail blob tail e7 tail
sulfadiazine H2O e4 e4 blob
sulfadiazine MeOH e5 e4 blob
sulfadiazine ACN e4 e4 blob
Sulfamethoxazole H2O e7 e7 blob e7 e7 blob
Sulfamethoxazole MeOH e7 e7 blob e7 e7 blob
Sulfamethoxazole ACN e7 e7 blob e7 e7 blob
Flumequin H2O e8 e8 tail e8 e8 tail
Flumequin MeOH e8 e8 tail e8 e8 tail
Flumequin ACN e8 e8 tail e8 e8 tail
Sulfisoxazole  H2O e7 e7 blob e7 e7 blob
Sulfisoxazole  MeOH e7 e7 blob e7 e7 blob
Sulfisoxazole  ACN e7 e6 blob e7 e7 blob
Sulfamethizole H2O lead lead blob e7 e7 blob
Sulfamethizole MeOH lead lead blob e7 e7 blob
Sulfamethizole ACN lead lead blob e7 e7 blob
tolbutamide H2O e8 e8 tail e8 e8 tail
tolbutamide MeOH e8 e8 tail e8 e8 tail
tolbutamide ACN e8 e8 tail e8 e8 tail
chlorpropamide H2O e7 e7 tail e8 e7 tail
chlorpropamide MeOH e8 e7 tail e8 e8 tail
chlorpropamide ACN e7 e7 tail e8 e8 tail
sulfamethazine H2O lead lead blob e8 e8 tail
sulfamethazine MeOH lead lead blob e8 e8 tail
sulfamethazine ACN lead lead blob e7 e7 blob
(Diacetoxyiodo)benzene H2O e6 e6 tail e8 e6 tail
(Diacetoxyiodo)benzene MeOH e6 e6 tail e8 e6 tail
(Diacetoxyiodo)benzene ACN e6 e6 tail e8 e6 tail
chlorthalidone H20 e6 e6 tail e8 e6 tail
chlorthalidone  MeOH e6 e6 tail e8 e6 tail
chlorthalidone ACN e6 e6 tail e8 e6 tail
Indapamide H2O e7 e7 tail e8 e7 tail
Indapamide MeOH e8 e7 tail e8 e7 tail blob
Indapamide ACN e7 e7 tail e8 e7 tail blob
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method 28 29 30 31 32 33 34 35 36
carbendazim H2O blob lead blob shoulder broad tail lead
carbendazim MeOH shoulder lead blob shoulder e7 tail lead
carbendazim ACN shoulder lead blob shoulder e7 tail lead
sulfadiazine H2O e5 e5 e8 e6 e5 e7
sulfadiazine MeOH e5 e5 e8 e4 lead e4
sulfadiazine ACN e5 e5 e8
Sulfamethoxazole H2O e8 e8 e8 e8 e7 e7
Sulfamethoxazole MeOH e8 e8 e8 e6 e5 e4
Sulfamethoxazole ACN e8 e8 e8 e5 e4
Flumequin H2O e8 e8 e8 e8 e8 e8
Flumequin MeOH e8 e8 e8 e7 e8 e6
Flumequin ACN e8 e8 e8 e7 e8 e6
Sulfisoxazole  H2O e8 e7 e8 e8 e7 e7
Sulfisoxazole  MeOH e8 e7 e8 e6 e4
Sulfisoxazole  ACN e8 e7 e8 e5 e4
Sulfamethizole H2O e7 e7 e8 e8 e7 e7
Sulfamethizole MeOH e7 e6 e8 e6 e4
Sulfamethizole ACN e6 e6 e8 e5 e4
tolbutamide H2O e7 e7 e8 e7 e7 e7 e7
tolbutamide MeOH e8 e7 e8 e6 e7 e5 e7
tolbutamide ACN e7 e7 e8 e5 e7 e5 e7
chlorpropamide H2O e7 e7 e8 e7 e7 e7 e7
chlorpropamide MeOH e7 e7 e8 e6 e7 e5 e7
chlorpropamide ACN e7 e7 e8 e5 e4 e6
sulfamethazine H2O e6 e6 e8 e8 e8 e8 e4
sulfamethazine MeOH e6 e6 e8 e6 tail e5 e4
sulfamethazine ACN e6 e6 e8 e5 shoulder e5
(Diacetoxyiodo)benzene H2O e7 e6 tail e7 e7 tail
(Diacetoxyiodo)benzene MeOH e7 e7 tail e5 e7
(Diacetoxyiodo)benzene ACN e7 e6 tail e4 e7
chlorthalidone H20 e7 e6 tail e7 e7 tail
chlorthalidone  MeOH e7 e7 tail e5 e7
chlorthalidone ACN e7 e6 tail e4 e7
Indapamide H2O e7 e7 tail e7 e7 tail e7
Indapamide MeOH e7 e7 tail e7 e7 tail broad 
Indapamide ACN e7 e6 tail e6 e6 tail broad 
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method 1 2 3 4 5 6 7 8 9
Lincomycin H20 e6 e6 e6 e5 e5 e6 e6 e6 e6
Lincomycin MeOH e5 e5 e6 e6 e6 e6 e6 e6
Lincomycin ACN e4 e4 e4 e4 e4 e4 e5 e5 e4
Clindamycin H20 e6 e6 e6 e5 e5 e5 e6 e6 e5
Clindamycin MeOH e5 e5 e5 e6 e5 e5 e6 e6 e4
Clindamycin ACN e4 e4 e4 e4 e4 e4 e5 e5 e4
Erythromycin H20 e5 e5 e5 e5 e5 e5 e6 e6 e6
Erythromycin MeOH e5 e5 e5 e5 e6 e6 e6 e6 e5
Erythromycin ACN e4 e4 e4 e5 e5 e5 e5 e5 e5
Clarithromycin H20 e6 e6 e6 e6 e5 e5 e5 e6 e6
Clarithromycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e5
Clarithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Azithromycin H20 e5 e5 e5 e5 e5 e4 e5 e5 e5
Azithromycin MeOH e5 e5 e5 e5 e5 e6 e5 e5 e4
Azithromycin ACN e4 e4 e4 e4 e5 e5 e4 e4 e4
Dirithromycin H20 e5
Dirithromycin MeOH e5 e5 e5 e5 e5 e5 e5 e5 e4
Dirithromycin ACN e4 e4 e4 e4 e4 e4 e4 e4 e4
Roxithromycin H20 e5 e5 e5 e5 e5 e4 e5 e5 e5
Roxithromycin MeOH e5 e5 e5 e5 e5 e6 e5 e6 e5
Roxithromycin ACN e4 e5 e4 e5 e5 e5 e4 e4 e4
Spiramycin H20 e4 e5 e4 e4
Spiramycin MeOH e5 e5 e5 e4 e5 e5 e4 e4 e4
Spiramycin ACN e4 e4 e4 e4 e4 e4
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method 10 11 12 13 14 15 16 17 18
Lincomycin H20 e6 e6 e6 e6 e6 e6 e6 e6 e6
Lincomycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e6
Lincomycin ACN e4 e5 e4 e5 e5 e5 e5 e5 e5
Clindamycin H20 e6 e6 e6 e6 e6 e6 e6 e6 e6
Clindamycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e6
Clindamycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Erythromycin H20 e5 e6 e5 e6 e6 e5 e6 e6 e6
Erythromycin MeOH e5 e6 e5 e6 e6 e6 e6 e6 e6
Erythromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Clarithromycin H20 e6 e6 e6 e6 e6 e5 e6 e6 e6
Clarithromycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e6
Clarithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Azithromycin H20 e5 e6 e5 e5 e5 e5 e5 e5 e5
Azithromycin MeOH e5 e6 e5 e5 e5 e6 e5 e5 e5
Azithromycin ACN e4 e5 e4 e5 e5 e5 e4 e4 e4
Dirithromycin H20 split shoulder tail
Dirithromycin MeOH shoulder split split tail shoulder tail tail tail tail
Dirithromycin ACN shoulder split split tail shoulder tail tail tail tail
Roxithromycin H20 e6 e6 e6 e5 e5 e5 e5 e5 e5
Roxithromycin MeOH e6 e6 e6 e5 e6 e6 e6 e6 e6
Roxithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Spiramycin H20 e4 e5
Spiramycin MeOH e4 e5 e5 e4 e5 e5 e5 e5
Spiramycin ACN e4 e4 e4 e4 e4 e4 e4 e4
94 





method 19 20 21 22 23 24 25 26 27
Lincomycin H20 e6 e5 e5 e5 e5 e5 e6 e6 e6
Lincomycin MeOH e5 e5 e5 e5 e5 e5 e6 e6 e5
Lincomycin ACN e5 e5 e5 e5 e5 e5 e6 e6 e5
Clindamycin H20 e5 e5 e5 e5 e5 e5 e5 e5 e5
Clindamycin MeOH e5 e5 e5 e5 e5 e5 e6 e5 e5
Clindamycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Erythromycin H20 e5 e5 e5 e5 e5 e5 e5 e5 e5
Erythromycin MeOH e5 e5 e5 e5 e5 e6 e6 e5 e6
Erythromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Clarithromycin H20 e6 e5 e6 e5 e5 e5 e6 e5 e6
Clarithromycin MeOH e6 e5 e5 e5 e5 e6 e6 e5 e6
Clarithromycin ACN e6 e6 e5 e6 e6 e5 e6 e6 e5
Azithromycin H20 e5 e5 e5 e5 e5 e4 e5 e5 e5
Azithromycin MeOH e5 e5 e5 e5 e5 e5 e5 e5 e5
Azithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Dirithromycin H20
Dirithromycin MeOH e5 e4 e5 e4 e4 e4 e5 e4 e5
Dirithromycin ACN e4 e4 e4 e4 e4 e4 e4 e4 e4
Roxithromycin H20 e5 e5 e5 e5 e4 e4 e5 e5 e5
Roxithromycin MeOH e5 e5 e5 e5 e4 e5 e5 e5 e5
Roxithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Spiramycin H20
Spiramycin MeOH e4 e4 e4 e4 e4 e4 e4 e4 e4
Spiramycin ACN e4 e4 e4 e4 e4 e4 e4 e4 e4
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method 28 29 30 31 32 33 34 35 36
Lincomycin H20 e6 e6 broad e6 e6 e6 e6 e6 e6
Lincomycin MeOH e6 e6 broad e6 e6 e6 e6 e6 e6
Lincomycin ACN e6 e5 broad e6 e5 e6 e6 e5 e6
Clindamycin H20 e6 e6 e6 e6 e5 e6 e6 e5 e6
Clindamycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e6
Clindamycin ACN e6 e5 e6 e6 e5 e6 e6 e5 e6
Erythromycin H20 e5 e6 e5 e6 e6 e5 e6 e6 e6
Erythromycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e6
Erythromycin ACN e6 e5 e6 e6 e5 e6 e6 e5 e6
Clarithromycin H20 e6 e6 e6 e6 e6 e5 e6 e6 e6
Clarithromycin MeOH e6 e6 e6 e6 e6 e6 e6 e6 e6
Clarithromycin ACN e6 e6 e6 e6 e5 e6 e6 e5 e6
Azithromycin H20 e5 e6 e5 e5 e5 e5 e5 e5 e5
Azithromycin MeOH e5 e6 e5 e5 e5 e6 e5 e5 e5
Azithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Dirithromycin H20
Dirithromycin MeOH e5 e6 e5 e5 e5 e5 e5 e5 e5
Dirithromycin ACN e5 e5 e5 e5 e5 e5 e5 e5 e5
Roxithromycin H20 e6 e6 e5 e5 e5 e5 e5 e5 e5
Roxithromycin MeOH e6 e6 e6 e5 e5 e6 e6 e6 e6
Roxithromycin ACN e6 e5 e6 e6 e5 e6 e6 e5 e6
Spiramycin H20
Spiramycin MeOH e5 e5 e4 e4 e4 e4 e5 e4 e4
Spiramycin ACN e5 e4 e4 e4 e4 e4 e4 e4 e4
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method 1 2 3 4 5 6 7 8 9
Norfloxacin H20 e4 e4 e4 e4 e4 e4 e4
Norfloxacin MeOH e4 e4 e4 e4 e4 e4 e4
Norfloxacin ACN e4 e4 e4 e4 e4 e4 e4
Enoxacin H20 e4 e4 e4 e4 e4 e4 e4
Enoxacin MeOH e4 e4 e4 e4 e4 e4 e4
Enoxacin ACN e4 e4 e4 e4 e4 e4 e4
Ciprofloxacin H20 e4 e3 e4 e4 e3 e4 e4
Ciprofloxacin MeOH e4 e3 e4 e4 e3 e4 e4
Ciprofloxacin ACN e4 e3 e4 e4 e3 e4 e4
Pefloxacin H20 e5 e4 e4 e4 e5 e5 blob e4 e5
Pefloxacin MeOH e5 e4 e5 e4 e4 e5 blob e4 e5
Pefloxacin ACN e5 e5 e5 e5 e5 e5 blob e5 e5
Lomefloxacin H20 e5 e4 e5 e4 e4 e4 blob e4 e5
Lomefloxacin MeOH e5 e4 e5 e4 e4 e5 blob e4 e5
Lomefloxacin ACN e5 e4 e5 e5 e5 e5 blob e4 e5
Nadifloxacin H20 e5 e4 e4 e5 e4 e4 blob e4 e4
Nadifloxacin MeOH e5 e4 e5 e5 e4 e5 blob e4 e5
Nadifloxacin ACN e5 e4 e5 e5 e4 e5 blob e4 e5
Ofloxacin H20 e5 e5 e5 e5 e5 e5 blob e5 e5
Ofloxacin MeOH e5 e5 e5 e5 e5 e5 blob e5 e6
Ofloxacin ACN e5 e5 e5 e5 e5 e5 blob e5 e6
Levofloxacin H20 e5 e5 e5 e5 e5 e5 blob e5 e5
Levofloxacin MeOH e5 e5 e5 e5 e5 e5 blob e5 e6
Levofloxacin ACN e5 e5 e5 e5 e5 e5 blob e5 e6
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method 10 11 12 13 14 15 16 17 18
Norfloxacin H20 tail tail tail tail tail tail tail tail
Norfloxacin MeOH tail tail tail tail tail tail tail tail
Norfloxacin ACN tail tail tail tail tail tail tail tail
Enoxacin H20 tail tail tail tail tail tail tail tail
Enoxacin MeOH tail tail tail tail tail tail tail tail
Enoxacin ACN tail tail tail tail tail tail tail tail
Ciprofloxacin H20 tail tail tail tail tail tail tail tail
Ciprofloxacin MeOH tail tail tail tail tail tail tail tail
Ciprofloxacin ACN tail tail tail tail tail tail tail tail
Pefloxacin H20 tail tail tail tail tail tail tail tail tail
Pefloxacin MeOH tail tail tail tail tail tail tail tail tail
Pefloxacin ACN tail tail tail tail tail tail tail tail tail
Lomefloxacin H20 tail tail tail tail tail tail tail tail tail
Lomefloxacin MeOH tail tail tail tail tail tail tail tail tail
Lomefloxacin ACN tail tail tail tail tail tail tail tail tail
Nadifloxacin H20 tail tail tail tail tail tail tail tail tail
Nadifloxacin MeOH tail tail tail tail tail tail tail tail tail
Nadifloxacin ACN tail tail tail tail tail tail tail tail tail
Ofloxacin H20 tail tail tail tail tail tail tail tail tail
Ofloxacin MeOH tail tail tail tail tail tail tail tail tail
Ofloxacin ACN tail tail tail tail tail tail tail tail tail
Levofloxacin H20 tail tail tail tail tail tail tail tail tail
Levofloxacin MeOH tail tail tail tail tail tail tail tail tail
Levofloxacin ACN tail tail tail tail tail tail tail tail tail
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method 19 20 21 22 23 24 25 26 27
Norfloxacin H20 e4 e4 blob e4 e4 tail e4 blob
Norfloxacin MeOH e4 e4 blob e4 e4 tail e4 blob
Norfloxacin ACN e5 e4 blob e5 e4 tail e4 blob
Enoxacin H20 e4 e4 blob e5 e4 tail lead e4 blob
Enoxacin MeOH e4 e5 blob e5 e4 tail lead e4 blob
Enoxacin ACN e5 e5 blob e5 e5 tail lead e5 blob
Ciprofloxacin H20 e4 e4 blob e4 e4 tail blob e4 blob
Ciprofloxacin MeOH e4 e4 blob e4 e4 tail blob e4 blob
Ciprofloxacin ACN e4 e5 blob e4 e5 tail blob e4 blob
Pefloxacin H20 e4 e4 blob e4 e4 tail blob e4 blob
Pefloxacin MeOH e5 e5 blob e5 e5 tail blob e5 blob
Pefloxacin ACN e5 e5 blob e5 e5 tail blob e5 blob
Lomefloxacin H20 e4 e4 blob e4 e4 tail blob e4 blob
Lomefloxacin MeOH e4 e4 blob e4 e4 tail blob e4 blob
Lomefloxacin ACN e5 e5 blob e5 e5 tail blob e5 blob
Nadifloxacin H20 e5 e4 blob e5 e5 blob blob e4 blob
Nadifloxacin MeOH e5 e5 blob e5 e5 blob blob e5 blob
Nadifloxacin ACN e5 e5 blob e5 e5 blob blob e5 blob
Ofloxacin H20 e5 e5 blob e5 e5 tail blob e5 blob
Ofloxacin MeOH e5 e5 blob e5 e5 tail blob e5 blob
Ofloxacin ACN e5 e5 blob e5 e5 tail blob e5 blob
Levofloxacin H20 e5 e5 blob e5 e5 tail blob e5 blob
Levofloxacin MeOH e5 e5 blob e5 e5 tail blob e5 blob
Levofloxacin ACN e5 e5 blob e5 e5 tail blob e5 blob
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method 28 29 30 31 32 33 34 35 36
Norfloxacin H20 tail tail tail tail tail tail tail tail tail
Norfloxacin MeOH tail tail tail tail tail tail tail tail tail
Norfloxacin ACN tail tail tail tail tail tail tail tail tail
Enoxacin H20 tail tail tail tail tail tail tail tail tail
Enoxacin MeOH tail tail tail tail tail tail tail tail tail
Enoxacin ACN tail tail tail tail tail tail tail tail tail
Ciprofloxacin H20 tail tail tail tail tail tail tail tail tail
Ciprofloxacin MeOH tail tail tail tail tail tail tail tail tail
Ciprofloxacin ACN tail tail tail tail tail tail tail tail tail
Pefloxacin H20 tail tail tail tail tail tail tail tail tail
Pefloxacin MeOH tail tail tail tail tail tail tail tail tail
Pefloxacin ACN tail tail tail tail tail tail tail tail tail
Lomefloxacin H20 tail tail tail tail tail tail tail tail tail
Lomefloxacin MeOH tail tail tail tail tail tail tail tail tail
Lomefloxacin ACN tail tail tail tail tail tail tail tail tail
Nadifloxacin H20 tail tail tail tail tail tail tail tail tail
Nadifloxacin MeOH tail tail tail tail tail tail tail tail tail
Nadifloxacin ACN tail tail tail tail tail tail tail tail tail
Ofloxacin H20 tail tail tail tail tail tail tail tail tail
Ofloxacin MeOH tail tail tail tail tail tail tail tail tail
Ofloxacin ACN tail tail tail tail tail tail tail tail tail
Levofloxacin H20 tail tail tail tail tail tail tail tail tail
Levofloxacin MeOH tail tail tail tail tail tail tail tail tail
Levofloxacin ACN tail tail tail tail tail tail tail tail tail
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method 1 2 3 4 5 6 7 8 9
Progesterone H2O e8 e8 e8 e8 e8 e8 e8 e8 e8
Progesterone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Progesterone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
17 hydroxy-progesterone H2O e8 e8 e8 e7 e8 e8 e7 e8 e8
17 hydroxy-progesterone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
17 hydroxy-progesterone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone H2O e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
cortisone H2O e7 e8 e8 e7 e8 e8 e7 e8 e7
cortisone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e7
cortisone ACN e8 e8 e8 e8 e8 e8 e8 e8 e7
hydrocortisone H2O e7 e7 e7 e7 e7 e7 e7 e7 e7
hydrocortisone MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
hydrocortisone ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
6a methyl prednisolone H2O e6 e7 e7 e6 e7 e7 e7 e7 e7
6a methyl prednisolone MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
6a methyl prednisolone ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Medroxyprogesterone acetate H2O e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone acetate MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone acetate ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
cortisone-21 acetate H2O e6 e7 e7 e6 e7 e7 e6 e7 e7
cortisone-21 acetate MeOH e7 e8 e8 e7 e8 e8 e7 e8 e7
cortisone-21 acetate ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Triamcinolone acetonide H2O e7 e7 e7 e6 e7 e7 e7 e7 e7
Triamcinolone acetonide MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Triamcinolone acetonide ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Triamcinolone diacetate H2O e6 e5 e4 e6 e5 e4 e6 e5 e5
Triamcinolone diacetate MeOH e7 e5 e4 e7 e5 e4 e7 e5 e5
Triamcinolone diacetate ACN e7 e5 e4 e7 e5 e4 e7 e5 e5
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method 10 11 12 13 14 15 16 17 18
Progesterone H2O e8 e8 e8 e8 e8 e8 e8 e8 e8
Progesterone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Progesterone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
17 hydroxy-progesterone H2O e7 e8 e8 e7 e8 e8 e7 e8 e8
17 hydroxy-progesterone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
17 hydroxy-progesterone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone H2O e7 e8 e8 e7 e8 e8 e8 e8 e8
Medroxyprogesterone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
cortisone H2O e7 e8 e8 e7 e8 e8 e7 e8 e8
cortisone MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
cortisone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
hydrocortisone H2O e7 e8 e8 e7 e8 e7 e7 e8 e7
hydrocortisone MeOH e7 e8 e8 e7 e8 e8 e7 e8 e8
hydrocortisone ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
6a methyl prednisolone H2O e7 e7 e7 e7 e7 e7 e7 e7 e7
6a methyl prednisolone MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
6a methyl prednisolone ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Medroxyprogesterone acetate H2O e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone acetate MeOH e8 e8 e8 e8 e8 e8 e8 e8 e8
Medroxyprogesterone acetate ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
cortisone-21 acetate H2O e6 e7 e7 e6 e7 e7 e6 e7 e7
cortisone-21 acetate MeOH e7 e8 e8 e7 e8 e8 e8 e8 e8
cortisone-21 acetate ACN e8 e8 e8 e8 e8 e8 e8 e8 e8
Triamcinolone acetonide H2O e7 e7 e7 e6 e7 e7 e7 e7 e7
Triamcinolone acetonide MeOH e7 e7 e7 e7 e7 e7 e7 e7 e7
Triamcinolone acetonide ACN e7 e7 e7 e7 e7 e7 e7 e7 e7
Triamcinolone diacetate H2O e7 e5 e5 e6 e5 e5 e6 e5 e5
Triamcinolone diacetate MeOH e7 e5 e5 e7 e5 e5 e7 e5 e5
Triamcinolone diacetate ACN e7 e5 e5 e7 e5 e5 e8 e5 e5
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Table W: Method Development for Hormones Methods 19 to 27 
 
 
method 19 20 21 22 23 24 25 26 27
Progesterone H2O e8 e8 tail e8 e8 tail e8 e8 tail
Progesterone MeOH e8 e8 tail e8 e8 tail e8 e8 tail
Progesterone ACN e8 e8 tail e8 e8 tail e8 e8 tail
17 hydroxy-progesterone H2O e8 e8 tail e7 e8 tail e7 e8 tail
17 hydroxy-progesterone MeOH e8 e8 tail e8 e8 tail e8 e8 tail
17 hydroxy-progesterone ACN e8 e8 tail e8 e8 tail e8 e8 tail
Medroxyprogesterone H2O e8 e8 tail e8 e8 tail e8 e8 tail
Medroxyprogesterone MeOH e8 e8 tail e8 e8 tail e8 e8 tail
Medroxyprogesterone ACN e8 e8 tail e8 e8 tail e8 e8 tail
cortisone H2O e7 e8 tail e8 e8 tail e8 e8 tail
cortisone MeOH e7 e8 tail e8 e8 tail e8 e8 tail
cortisone ACN e7 e8 tail e8 e8 tail e8 e8 tail
hydrocortisone H2O e7 e8 tail e7 e8 tail e7 e8 tail
hydrocortisone MeOH e7 e8 tail e7 e8 tail e7 e8 tail
hydrocortisone ACN e7 e8 tail e7 e8 tail e7 e8 tail
6a methyl prednisolone H2O e6 e7 tail e6 e7 tail e6 e7 tail
6a methyl prednisolone MeOH e6 e7 tail e6 e7 tail e7 e7 tail
6a methyl prednisolone ACN e6 e7 tail e6 e7 tail e7 e7 tail
Medroxyprogesterone acetate H2O e8 e8 tail e8 e8 tail e8 e8 tail
Medroxyprogesterone acetate MeOH e8 e8 tail e8 e8 tail e8 e8 tail
Medroxyprogesterone acetate ACN e8 e8 tail e8 e8 tail e8 e8 tail
cortisone-21 acetate H2O e7 e8 tail e7 e8 tail e7 e8 tail
cortisone-21 acetate MeOH e8 e8 tail e7 e8 tail e8 e8 tail
cortisone-21 acetate ACN e7 e8 tail e7 e8 tail e8 e8 tail
Triamcinolone acetonide H2O e6 e7 tail e6 e7 tail e7 e7 tail
Triamcinolone acetonide MeOH e7 e7 tail e7 e7 tail e7 e7 tail
Triamcinolone acetonide ACN e7 e7 tail e6 e7 tail e7 e7 tail
Triamcinolone diacetate H2O e7 e7 tail e7 e7 tail e7 e7 tail
Triamcinolone diacetate MeOH e7 e7 tail e7 e7 tail e7 e7 tail
Triamcinolone diacetate ACN e7 e8 tail e7 e7 tail e7 e8 tail
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method 28 29 30 # 31 32 33 # 34 35 36
Progesterone H2O e7 e7 tail e7 e7 tail e7 e7 tail
Progesterone MeOH e8 e8 tail e8 e8 tail e8 e8 tail
Progesterone ACN e8 e8 tail e8 e8 tail e8 e8 tail
17 hydroxy-progesterone H2O e7 e7 tail e7 e7 tail e7 e7 tail
17 hydroxy-progesterone MeOH e7 e7 tail e7 e7 tail e7 e7 tail
17 hydroxy-progesterone ACN e7 e8 tail e7 e8 tail e5 e8 tail
Medroxyprogesterone H2O e7 e7 tail e7 e7 tail e7 e7 tail
Medroxyprogesterone MeOH e7 e8 tail e7 e8 tail e7 e8 tail
Medroxyprogesterone ACN e7 e8 tail e7 e8 tail e5 e8 tail
cortisone H2O e7 e7 tail e7 e7 tail e7 e7 tail
cortisone MeOH e7 e7 tail e7 e7 tail e7 e7 tail
cortisone ACN e7 e8 tail e7 e8 tail e8 tail
hydrocortisone H2O e6 e7 tail e6 e7 tail e6 e7 tail
hydrocortisone MeOH e7 e7 tail e7 e7 tail e7 e7 tail
hydrocortisone ACN e7 e7 tail e7 e7 tail e7 tail
6a methyl prednisolone H2O e6 e6 tail e6 e6 tail e6 e6 tail
6a methyl prednisolone MeOH e6 e6 tail e6 e6 tail e6 e6 tail
6a methyl prednisolone ACN e6 e7 tail e6 e7 tail e7 tail
Medroxyprogesterone acetate H2O e7 e7 tail e7 e7 tail e7 e7 tail
Medroxyprogesterone acetate MeOH e7 e7 tail e7 e7 tail e7 e7 tail
Medroxyprogesterone acetate ACN e7 e8 tail e7 e8 tail e5 e8 tail
cortisone-21 acetate H2O e6 e7 tail e6 e7 tail e6 e6 tail
cortisone-21 acetate MeOH e7 e7 tail e7 e7 tail e7 e7 tail
cortisone-21 acetate ACN e7 e8 tail e7 e7 tail e7 tail
Triamcinolone acetonide H2O e6 e6 tail e6 e6 tail e6 e6 tail
Triamcinolone acetonide MeOH e6 e6 tail e6 e6 tail e6 e6 tail
Triamcinolone acetonide ACN e6 e6 tail e6 e6 tail e6 tail
Triamcinolone diacetate H2O e6 e6 tail e6 e6 tail e6 e6 tail
Triamcinolone diacetate MeOH e6 e6 tail e6 e6 tail e6 e6 tail
Triamcinolone diacetate ACN e6 e7 tail e6 e7 tail e7 tail
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7 14 21 28
H20 spike +4 °C A 10973.3 8640.0 12081.1 8363.9
H20 spike +4 °C B 12069.7 8418.1 11768.7 8049.7
H20 spike +4 °C A 16308.6 15196.8 11984.0 4547.9
H20 spike +4 °C B 17090.2 13632.6 11862.1 4189.5
H20 spike -20° C A 14796.5 8409.0 15524.3 8425.3
H20 spike -20° C B 13913.0 8266.2 14874.7 7598.8
H20 spike -20° C A 5476.6 4298.0 6086.0 2325.9
H20 spike -20° C B 5203.5 4767.2 6084.9 2987.7
Urine Spike  +4 °C A 53947.1 36430.3 39470.5 26015.8
Urine Spike  +4 °C B 60070.1 32944.3 42996.3 21036.6
Urine Spike  +4 °C A 48966.0 26790.2 26848.6 12172.4
Urine Spike  +4 °C B 42992.9 24481.1 25901.8 12218.7
Urine Spike  -20° C A 43984.3 36433.0 47504.4 21681.1
Urine Spike  -20° C B 37044.3 33584.3 42619.5 19444.2
Urine Spike  -20° C A 58151.0 28493.8 29986.3 12621.8












Figure 30. Graph Showing Stability Changes in Terms of Area Count for Tamoxifen 

















































































































































































































































7 14 21 28
H20 spike +4 °C A 342.7 215.1 205.1 549.4
H20 spike +4 °C B 216.3 184.5 205.1 420.2
H20 spike +4 °C A 302.9 148.3 75.5 234.8
H20 spike +4 °C B 413.1 128.0 123.1 285.2
H20 spike -20° C A 198.4 124.1 243.2 302.0
H20 spike -20° C B 330.9 65.8 246.7 303.4
H20 spike -20° C A 141.0 NA 102.3 213.7
H20 spike -20° C B 152.6 NA 76.3 157.5
Urine Spike  +4 °C A 294.9 75.5 325.0 79.1
Urine Spike  +4 °C B 345.9 74.2 302.3 443.9
Urine Spike  +4 °C A NA NA NA NA
Urine Spike  +4 °C B NA NA NA NA
Urine Spike  -20° C A 279.8 129.8 391.9 34.0
Urine Spike  -20° C B 236.5 197.9 375.9 92.5
Urine Spike  -20° C A 281.7 46.1 108.0 40.0













Figure 31. Graph Showing Stability Changes in Terms of Area Count for Cyclofenil 















































































































































































































































7 14 21 28
H20 spike +4 °C A 10757.7 9259.0 10378.5 6821.4
H20 spike +4 °C B 11630.0 8901.7 10362.2 7764.5
H20 spike +4 °C A 20572.4 14870.8 11499.5 4777.2
H20 spike +4 °C B 20471.0 14171.1 11157.0 5261.3
H20 spike -20° C A 13798.6 7623.8 15565.3 8318.6
H20 spike -20° C B 12990.4 7316.2 14697.5 6383.3
H20 spike -20° C A 11418.0 5052.8 7039.7 2791.5
H20 spike -20° C B 10474.4 4562.9 5612.0 3298.5
Urine Spike  +4 °C A 55938.4 37200.9 35691.3 18749.9
Urine Spike  +4 °C B 65813.5 34123.1 37551.3 24331.9
Urine Spike  +4 °C A 54448.0 27869.9 26464.1 10073.1
Urine Spike  +4 °C B 48151.9 25671.7 24212.0 10383.9
Urine Spike  -20° C A 56639.0 42066.9 42743.6 16563.2
Urine Spike  -20° C B 50852.8 39797.7 37985.4 14760.2
Urine Spike  -20° C A 51823.1 31585.9 27900.9 9550.3












Figure 32. Graph Showing Stability Changes in Terms of Area Count for Clomiphene 




















































































































































































































































7 14 21 28
H20 spike +4 °C A 2305.8 1703.5 2445.8 1632.8
H20 spike +4 °C B 2330.5 1548.1 2545.6 1595.2
H20 spike +4 °C A 3701.3 3126.1 2931.4 1089.2
H20 spike +4 °C B 3891.5 2817.0 2934.3 1202.7
H20 spike -20° C A 2887.5 1663.7 2898.7 1575.7
H20 spike -20° C B 2818.6 1337.4 2874.7 1464.9
H20 spike -20° C A 886.3 745.6 1016.0 497.0
H20 spike -20° C B 892.3 716.5 1156.3 705.5
Urine Spike  +4 °C A 9389.6 6411.4 6941.9 4377.8
Urine Spike  +4 °C B 10638.6 5831.5 6941.9 3456.2
Urine Spike  +4 °C A 8932.1 4871.0 4924.7 2391.7
Urine Spike  +4 °C B 7700.9 4488.3 4439.3 2249.3
Urine Spike  -20° C A 9971.1 6063.2 7923.8 3379.3
Urine Spike  -20° C B 8741.2 5726.5 6895.9 3036.4
Urine Spike  -20° C A 7952.8 5010.8 5109.9 2127.9












Figure 33. Graph Showing Stability Changes in Terms of Area Count for 

















































































































































































































































7 14 21 28
H20 spike +4 °C A 10808.3 9488.6 8305.4 3650.1
H20 spike +4 °C B 4681.0 7554.9 9380.4 3611.1
H20 spike +4 °C A 10619.4 9815.1 10394.6 4543.5
H20 spike +4 °C B 10942.3 9176.8 11631.0 4162.8
H20 spike -20° C A 12357.8 9627.6 10345.3 4343.4
H20 spike -20° C B 13221.8 9307.1 12050.9 5330.6
H20 spike -20° C A 13022.0 10465.7 11372.1 4325.6
H20 spike -20° C B 13715.0 10488.8 12299.8 5337.1
Urine Spike  +4 °C A NA NA 26787.6 17061.8
Urine Spike  +4 °C B NA NA 24419.9 16946.0
Urine Spike  +4 °C A NA NA 31856.6 16885.8
Urine Spike  +4 °C B NA NA 32792.3 16863.3
Urine Spike  -20° C A NA NA 35327.6 19722.9
Urine Spike  -20° C B NA NA 34312.5 18947.7
Urine Spike  -20° C A NA NA 36827.0 19504.0













Figure 34. Graph Showing Stability Changes in Terms of Area Count for Sulfadiazine 




















































































































































































































































7 14 21 28
H20 spike +4 °C A 167861.3 90717.1 107941.8 39836.9
H20 spike +4 °C B 116418.7 76405.1 121046.3 46913.6
H20 spike +4 °C A 163051.3 125166.5 151605.4 47647.0
H20 spike +4 °C B 158324.7 125594.7 153210.6 46530.6
H20 spike -20° C A 183517.1 129297.1 121648.8 41783.9
H20 spike -20° C B 184820.1 127764.5 130490.1 40051.3
H20 spike -20° C A 170853.3 131125.5 155206.7 65380.7
H20 spike -20° C B 172459.7 127978.9 159117.5 56561.6
Urine Spike  +4 °C A 36280.5 1846.9 3812.9 2316.7
Urine Spike  +4 °C B 34560.8 2086.5 3345.5 2065.7
Urine Spike  +4 °C A 35598.7 1910.0 4120.8 2253.3
Urine Spike  +4 °C B 32963.1 2024.4 4093.3 1978.0
Urine Spike  -20° C A 35040.1 2003.9 3990.0 2248.6
Urine Spike  -20° C B 27807.7 1920.7 3760.4 2533.8
Urine Spike  -20° C A 31550.6 2221.9 4006.1 2413.0













Figure 35. Graph Showing Stability Changes in Terms of Area Count for 


















































































































































































































































7 14 21 28
H20 spike +4 °C A 113824.5 60360.5 75498.2 41640.3
H20 spike +4 °C B 97626.0 32287.1 79205.6 40166.4
H20 spike +4 °C A 95632.3 62666.3 78446.0 45381.6
H20 spike +4 °C B 91143.5 60910.6 74752.5 39492.4
H20 spike -20° C A 106434.1 64303.5 89315.7 42242.7
H20 spike -20° C B 104297.2 61407.2 78084.1 48276.7
H20 spike -20° C A 85400.7 59114.1 79053.4 41788.4
H20 spike -20° C B 89309.2 58830.4 69231.3 45299.1
Urine Spike  +4 °C A 36127.5 27342.6 8237.6 2295.5
Urine Spike  +4 °C B 29976.9 27736.6 8004.8 2798.4
Urine Spike  +4 °C A 28801.2 27265.3 8283.3 2807.2
Urine Spike  +4 °C B 30351.3 31681.6 8266.8 NA
Urine Spike  -20° C A 37345.4 31820.8 9413.3 2981.3
Urine Spike  -20° C B 36093.2 29725.4 10391.1 1825.6
Urine Spike  -20° C A 39120.1 33236.0 10334.3 3068.3












Figure 36. Graph Showing Stability Changes in Terms of Area Count for Flumequin 






































































































































































































































7 14 21 28
118 





7 14 21 28
H20 spike +4 °C A 183797.1 102851.9 240853.5 70751.6
H20 spike +4 °C B 147986.7 84341.4 258904.1 65388.4
H20 spike +4 °C A 194669.9 131385.4 300470.1 96919.5
H20 spike +4 °C B 193585.9 126882.1 322231.8 103335.4
H20 spike -20° C A 218415.1 127497.8 294534.9 77054.4
H20 spike -20° C B 219642.6 120751.2 295381.3 96078.4
H20 spike -20° C A 214602.2 139794.5 329268.8 106650.0
H20 spike -20° C B 220580.9 135099.2 333660.9 103178.1
Urine Spike  +4 °C A 7786.8 6978.5 NA 5579.2
Urine Spike  +4 °C B 8102.6 7047.3 NA 5271.8
Urine Spike  +4 °C A 7933.0 7236.3 NA 6002.6
Urine Spike  +4 °C B 8432.6 7693.7 NA 5673.8
Urine Spike  -20° C A 6638.3 7959.7 NA 5425.3
Urine Spike  -20° C B 7664.0 7048.9 NA 4922.8
Urine Spike  -20° C A 8343.9 6781.6 NA 4210.4












Figure 37. Graph Showing Stability Changes in Terms of Area Count for 



















































































































































































































































7 14 21 28
H20 spike +4 °C A 138244.2 98219.8 91343.0 29114.0
H20 spike +4 °C B 119457.8 77463.6 94743.2 26136.0
H20 spike +4 °C A 133252.3 99057.3 99275.7 30473.9
H20 spike +4 °C B 129473.8 101298.9 98133.2 30095.0
H20 spike -20° C A 146227.5 104584.3 99753.8 30517.2
H20 spike -20° C B 145109.8 100542.1 101998.4 35365.1
H20 spike -20° C A 132333.9 102075.3 91019.9 36318.7
H20 spike -20° C B 134496.9 99938.9 99354.6 32089.7
Urine Spike  +4 °C A 12739.1 8250.4 NA 413.1
Urine Spike  +4 °C B 12992.5 8247.7 NA NA
Urine Spike  +4 °C A 13155.9 8079.0 NA 765.4
Urine Spike  +4 °C B 13144.9 8801.4 NA 1100.8
Urine Spike  -20° C A 13289.9 7696.0 NA 842.2
Urine Spike  -20° C B 13119.5 8506.8 NA 946.2
Urine Spike  -20° C A 13592.6 8231.2 NA 1334.9












Figure 38. Graph Showing Stability Changes in Terms of Area Count for 





































































































































































































































7 14 21 28
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7 14 21 28
H20 spike +4 °C A 43716.7 27685.2 24923.3 11375.6
H20 spike +4 °C B 36717.9 24460.2 26486.4 12037.8
H20 spike +4 °C A 42323.4 29031.3 28887.7 10363.1
H20 spike +4 °C B 39833.4 29730.0 28512.8 13102.5
H20 spike -20° C A 46859.7 30915.4 27542.2 12395.9
H20 spike -20° C B 45434.5 29174.4 27463.0 13840.3
H20 spike -20° C A 41842.6 29549.3 29031.5 12181.2
H20 spike -20° C B 41981.7 29020.4 27801.2 12959.5
Urine Spike  +4 °C A 1063.2 570.7 1346.7 800.1
Urine Spike  +4 °C B 1177.4 606.8 1099.1 666.3
Urine Spike  +4 °C A 1181.5 799.4 1083.5 1002.2
Urine Spike  +4 °C B 1053.8 639.5 1593.6 894.4
Urine Spike  -20° C A 1474.1 381.0 1195.3 1070.9
Urine Spike  -20° C B 975.3 608.7 1193.8 1157.2
Urine Spike  -20° C A 1485.0 495.1 1099.1 1141.6













Figure 39. Graph Showing Stability Changes in Terms of Area Count for 



















































































































































































































































7 14 21 28
H20 spike +4 °C A 260123.3 167188.2 236348.9 129630.4
H20 spike +4 °C B 226062.3 146367.1 253152.0 116030.0
H20 spike +4 °C A 255605.8 199135.5 277909.3 147706.1
H20 spike +4 °C B 254613.0 194557.7 296659.4 149699.3
H20 spike -20° C A 286755.8 198543.5 270862.1 128330.1
H20 spike -20° C B 288897.5 189694.6 275356.5 153381.8
H20 spike -20° C A 277103.3 210093.3 298300.4 168691.4
H20 spike -20° C B 280014.8 210263.8 300740.7 167866.3
Urine Spike  +4 °C A 23559.3 21759.6 20557.0 11999.6
Urine Spike  +4 °C B 20823.5 20727.9 19028.8 12509.2
Urine Spike  +4 °C A 23587.3 22955.6 20798.9 13651.1
Urine Spike  +4 °C B 23353.1 24115.6 21076.5 13048.3
Urine Spike  -20° C A 21955.6 22046.1 20623.4 12231.3
Urine Spike  -20° C B 20660.2 21864.6 20448.1 12121.8
Urine Spike  -20° C A 23645.0 24834.8 20826.3 11277.7













Figure 40. Graph Showing Stability Changes in Terms of Area Count for 
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Table AJ: Stability Changes with Respect to Area Count for Diacetoxyiodobenzene 





7 14 21 28
H20 spike +4 °C A 147873.8 112555.1 108557.2 71101.8
H20 spike +4 °C B 125471.4 104393.1 113011.5 63826.3
H20 spike +4 °C A 134991.3 112605.9 118962.2 68504.1
H20 spike +4 °C B 127480.1 114439.2 115411.5 69656.7
H20 spike -20° C A 147586.4 115736.6 113699.9 68733.7
H20 spike -20° C B 146939.1 110761.7 115859.7 73381.8
H20 spike -20° C A 132105.2 112931.6 116884.9 69119.0
H20 spike -20° C B 131946.0 108865.6 113334.0 73765.5
Urine Spike  +4 °C A 10553.4 7478.5 5580.2 3862.6
Urine Spike  +4 °C B 10436.3 8042.9 5502.8 4081.2
Urine Spike  +4 °C A 10966.6 7523.8 5574.1 4264.2
Urine Spike  +4 °C B 10632.8 7935.0 5634.4 4802.8
Urine Spike  -20° C A 10237.3 7932.8 5456.1 4247.1
Urine Spike  -20° C B 9294.0 7049.0 5463.2 3861.4
Urine Spike  -20° C A 10674.3 8424.9 5841.5 4480.0












Figure 40. Graph Showing Stability Changes in Terms of Area Count for 














































































































































































































































7 14 21 28
H20 spike +4 °C A 144069.0 100230.1 100293.3 65212.5
H20 spike +4 °C B 122046.5 95762.6 103704.6 59519.3
H20 spike +4 °C A 131161.3 98644.3 105064.6 57931.2
H20 spike +4 °C B 124016.7 99140.5 90217.3 59964.5
H20 spike -20° C A 144051.3 100816.7 105882.6 60352.4
H20 spike -20° C B 142220.9 97074.6 109661.4 67501.9
H20 spike -20° C A 125334.4 98849.2 102736.5 64526.2
H20 spike -20° C B 127271.3 97608.3 100634.6 66276.1
Urine Spike  +4 °C A 9962.4 6857.0 6374.5 4792.0
Urine Spike  +4 °C B 9904.1 7264.1 6227.7 4974.5
Urine Spike  +4 °C A 10492.0 7436.1 6806.8 5051.9
Urine Spike  +4 °C B 9607.0 7289.8 6905.8 5085.2
Urine Spike  -20° C A 9173.1 7216.9 6302.7 4053.3
Urine Spike  -20° C B 9049.7 6849.6 6628.8 4306.5
Urine Spike  -20° C A 9852.4 7824.2 6938.2 4555.6












Figure 42. Graph Showing Stability Changes in Terms of Area Count for 


















































































































































































































































7 14 21 28
H20 spike +4 °C A NA 107931.6 13150.3 61113.8
H20 spike +4 °C B NA 39438.7 13059.0 61135.2
H20 spike +4 °C A NA 159092.9 18251.1 88710.1
H20 spike +4 °C B NA 157982.9 17250.1 92923.7
H20 spike -20° C A NA 128472.3 14626.0 76619.2
H20 spike -20° C B NA 118985.6 16444.6 97732.3
H20 spike -20° C A NA 138318.8 17020.1 91138.4
H20 spike -20° C B NA 133667.9 16555.9 96717.4
Urine Spike  +4 °C A NA 14109.7 2146.4 10980.5
Urine Spike  +4 °C B NA 13762.3 1996.5 11329.7
Urine Spike  +4 °C A NA 15522.5 2522.6 12192.8
Urine Spike  +4 °C B NA 14762.1 2704.5 12137.4
Urine Spike  -20° C A NA 14571.5 2458.8 11427.2
Urine Spike  -20° C B NA 14671.5 2268.2 11469.4
Urine Spike  -20° C A NA 16089.1 2520.5 11810.2













Figure 43. Graph Showing Stability Changes in Terms of Area Count for Indapamide 
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7 14 21 28
H20 spike +4 °C A 251608.7 228253.8 221009.3 97300.5
H20 spike +4 °C B 229943.0 90002.9 238014.4 95323.6
H20 spike +4 °C A 255258.7 250900.0 249764.2 102583.1
H20 spike +4 °C B 254970.3 247821.8 270555.6 106603.6
H20 spike -20° C A 298321.4 261587.1 273989.5 110519.7
H20 spike -20° C B 308053.4 254188.8 288908.2 121253.7
H20 spike -20° C A 292550.6 274913.2 286158.3 119342.6
H20 spike -20° C B 304713.4 276881.8 286516.1 129403.4
Urine Spike  +4 °C A 50777.4 44950.8 40085.7 25911.6
Urine Spike  +4 °C B 50446.0 44726.7 40542.9 23916.7
Urine Spike  +4 °C A 54721.3 48495.7 42712.4 28745.5
Urine Spike  +4 °C B 52369.0 50408.7 45461.5 29652.0
Urine Spike  -20° C A 49951.1 46831.0 42513.8 25517.2
Urine Spike  -20° C B 45311.0 45314.9 40795.1 23265.3
Urine Spike  -20° C A 53093.1 53759.4 48459.0 28005.1












Figure 44. Graph Showing Stability Changes in Terms of Area Count for 












































































































































































































































Table AN: Stability Changes with Respect to Area Count for JWH-073 Over 28 Days 
 
 
7 14 21 28
H20 spike +4 °C A 18144.2 11034.1 13594.6 30905.1
H20 spike +4 °C B 20178.1 12156.6 13538.1 31099.8
H20 spike +4 °C A 37868.4 20744.6 12666.8 47148.3
H20 spike +4 °C B 41263.6 22235.5 11767.5 44761.6
H20 spike -20° C A 19495.7 9139.4 12152.9 27210.0
H20 spike -20° C B 16936.2 9263.0 11887.7 28817.0
H20 spike -20° C A 10994.9 5404.6 6911.0 18706.1
H20 spike -20° C B 11067.7 6415.3 7831.6 19121.7
Urine Spike  +4 °C A 61371.2 32228.1 37259.1 100329.9
Urine Spike  +4 °C B 63588.3 29223.4 37151.1 101010.7
Urine Spike  +4 °C A 65833.1 31651.0 33143.0 105809.4
Urine Spike  +4 °C B 65369.0 NA NA 110783.2
Urine Spike  -20° C A 61076.4297 NA NA 105280.2
Urine Spike  -20° C B 52918.9947 71126.5 NA 99258.0
Urine Spike  -20° C A 54492.2957 158204.0 NA 90106.9













Figure 45. Graph Showing Stability Changes in Terms of Area Count for JWH-073 









































































































































































































































7 14 21 28
136 
 





7 14 21 28
H20 spike +4 °C A 24581.4 29593.4 24986.4 39944.2
H20 spike +4 °C B 26269.9 15724.6 24887.0 40121.3
H20 spike +4 °C A 26517.0 32006.5 19882.3 35292.0
H20 spike +4 °C B 28672.1 31976.9 19045.1 33567.4
H20 spike -20° C A 31683.1 30201.7 21628.6 35710.9
H20 spike -20° C B 27049.9 28473.4 23432.2 39301.5
H20 spike -20° C A 24589.5 22806.6 18234.5 30099.0
H20 spike -20° C B 24841.1 25031.3 18804.4 29955.1
Urine Spike  +4 °C A 28662.0 28785.1 22989.3 41871.9
Urine Spike  +4 °C B 28827.4 26480.1 22912.6 40248.3
Urine Spike  +4 °C A 28609.1 27947.4 22312.1 42202.5
Urine Spike  +4 °C B 26959.0 NA NA 42448.9
Urine Spike  -20° C A 28186.2 NA NA 42478.5
Urine Spike  -20° C B 25924.7 38996.3 NA 38738.1
Urine Spike  -20° C A 28962.1 53761.5 NA 43346.1












Figure 46. Graph Showing Stability Changes in Terms of Area Count for AB-
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7 14 21 28
H20 spike +4 °C A 86117.0 51316.4 57516.1 170693.2
H20 spike +4 °C B 95753.8 57306.7 57830.2 166964.5
H20 spike +4 °C A 287449.4 157672.6 103379.5 543310.3
H20 spike +4 °C B 316818.1 173658.8 93504.4 495328.5
H20 spike -20° C A 95457.9 42460.2 76855.3 214949.0
H20 spike -20° C B 85018.5 42923.9 72201.3 223735.9
H20 spike -20° C A 43136.9 20333.1 26534.3 95411.1
H20 spike -20° C B 45144.3 24502.4 29836.7 96212.3
Urine Spike  +4 °C A 404306.5 212109.3 137224.9 547782.9
Urine Spike  +4 °C B 426330.9 193672.0 150878.1 546596.6
Urine Spike  +4 °C A 561533.6 255600.4 144486.3 651780.5
Urine Spike  +4 °C B 554941.1 NA NA 709070.7
Urine Spike  -20° C A 455825.6 NA NA 599960.3
Urine Spike  -20° C B 387439.1 NA NA 540210.5
Urine Spike  -20° C A 370610.7 NA NA 481782.5












Figure 47. Graph Showing Stability Changes in Terms of Area Count for JWH-018 
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7 14 21 28
H20 spike +4 °C A 40301.9 27142.3 29597.9 74514.1
H20 spike +4 °C B 45138.5 26194.7 30163.8 75919.3
H20 spike +4 °C A 71661.5 42638.0 23758.5 84621.5
H20 spike +4 °C B 78155.3 46018.5 22500.3 80707.6
H20 spike -20° C A 40744.7 21611.2 21602.3 52039.3
H20 spike -20° C B 36704.2 21727.7 20510.2 55545.8
H20 spike -20° C A 26376.2 11858.6 14730.1 43967.0
H20 spike -20° C B 25924.0 13660.9 16250.4 44173.4
Urine Spike  +4 °C A 104397.8 59331.1 60131.8 173641.2
Urine Spike  +4 °C B 111169.2 67761.5 59427.4 170546.5
Urine Spike  +4 °C A 114960.6 55544.3 50748.2 168935.4
Urine Spike  +4 °C B 115390.4 NA NA 179148.6
Urine Spike  -20° C A 110460.3 NA NA 171078.8
Urine Spike  -20° C B 95666.2 NA NA 156549.3
Urine Spike  -20° C A 99804.4 NA NA 158846.3












Figure 48. Graph Showing Stability Changes in Terms of Area Count for AM 2201 





















































































































































































































































7 14 21 28
H20 spike +4 °C A 45550.3 43267.6 59319.7 60552.1
H20 spike +4 °C B 50945.8 39105.5 60058.3 60083.9
H20 spike +4 °C A 85000.9 84256.7 51839.3 66789.8
H20 spike +4 °C B 92766.3 85658.3 54080.3 63813.1
H20 spike -20° C A 45858.9 34759.6 39677.9 39157.6
H20 spike -20° C B 38476.5 35923.1 37730.6 41947.4
H20 spike -20° C A 28064.7 19672.1 27997.4 35872.1
H20 spike -20° C B 28436.4 24079.2 33328.9 36320.6
Urine Spike  +4 °C A 136961.6 111872.4 141115.0 159859.6
Urine Spike  +4 °C B 148560.8 99865.0 138397.8 156208.4
Urine Spike  +4 °C A 149973.4 105635.7 132737.4 146314.3
Urine Spike  +4 °C B 147973.8 NA NA 149602.2
Urine Spike  -20° C A 146939.2 163109.9 NA 157364.6
Urine Spike  -20° C B 130928.1 133014.6 NA 144111.9
Urine Spike  -20° C A 143685.1 133859.6 NA 152021.9














Figure 49. Graph Showing Stability Changes in Terms of Area Count for 5F-PB-22 
















































































































































































































































7 14 21 28
H20 spike +4 °C A 2153518.6 NA 1835149.8 4211285.0
H20 spike +4 °C B 2005891.5 NA 4818633.7 4176296.2
H20 spike +4 °C A 621113.7 NA NA 804650.9
H20 spike +4 °C B 670953.1 NA 1116215.5 834249.9
H20 spike -20° C A 2443845.3 NA NA 3855914.2
H20 spike -20° C B 2108629.1 NA 2801686.3 4354431.2
H20 spike -20° C A 1747109.0 NA 4187745.3 3457142.3
H20 spike -20° C B 1848265.3 NA NA 3544185.3
Urine Spike  +4 °C A 1496341.9 NA NA 2638420.5
Urine Spike  +4 °C B 2275837.8 NA 1260286.9 2668271.9
Urine Spike  +4 °C A 2155278.5 NA 3247059.4 2514746.8
Urine Spike  +4 °C B 1964716.3 NA 3079866.9 2560997.2
Urine Spike  -20° C A 1360135.3 NA 3335469.8 958093.7
Urine Spike  -20° C B 1835957.9 NA 3630411.4 2862631.3
Urine Spike  -20° C A 2135195.9 NA 3478917.8 2949825.9













Figure 50. Graph Showing Stability Changes in Terms of Area Count for Ralaxofene 


















































































































































































































































7 14 21 28
H20 spike +4 °C A 195984.7 NA 115449.8 151568.4
H20 spike +4 °C B 216083.4 NA 116677.5 150807.0
H20 spike +4 °C A 179642.1 NA 71086.3 93025.2
H20 spike +4 °C B 184246.6 150903.8 73001.1 83984.3
H20 spike -20° C A NA NA 90691.0 104022.1
H20 spike -20° C B 339445.8 NA 86238.1 108242.5
H20 spike -20° C A 136638.5 87188.0 62372.5 71226.5
H20 spike -20° C B 125291.9 83543.4 66121.7 78592.9
Urine Spike  +4 °C A 194003.5 NA 158107.9 189666.0
Urine Spike  +4 °C B 239696.4 NA 121244.6 175150.2
Urine Spike  +4 °C A 238626.5 NA 197623.5 173654.4
Urine Spike  +4 °C B 226760.5 159253.2 165534.3 175635.0
Urine Spike  -20° C A 220121.5 NA 114249.4 127064.8
Urine Spike  -20° C B 210284.3 NA 233787.6 215636.4
Urine Spike  -20° C A 256318.5 158204.0 201054.8 183139.1












Figure 51. Graph Showing Stability Changes in Terms of Area Count for 
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Table AU: Stability Changes with Respect to Area Count for 17 Hydroxy 




7 14 21 28
H20 spike +4 °C A 64967.0 NA 44857.9 72376.6
H20 spike +4 °C B 72266.8 NA 44654.9 67402.3
H20 spike +4 °C A 60667.0 NA 34858.7 54304.6
H20 spike +4 °C B 61851.6 46698.0 34854.6 47266.6
H20 spike -20° C A NA NA 41629.0 60227.0
H20 spike -20° C B 117951.1 NA 42176.2 63247.4
H20 spike -20° C A 51309.8 35969.7 33650.1 45743.5
H20 spike -20° C B 45832.7 33271.3 34568.8 50199.6
Urine Spike  +4 °C A 60546.1 NA 36870.6 69804.4
Urine Spike  +4 °C B 73815.6 NA 54991.9 64566.7
Urine Spike  +4 °C A 81989.3 NA 87072.1 73866.2
Urine Spike  +4 °C B 79865.1 56050.4 68702.8 74751.9
Urine Spike  -20° C A 81160.2 NA 46628.0 55051.9
Urine Spike  -20° C B 72183.1 38996.3 94108.3 91995.8
Urine Spike  -20° C A 64333.1 53761.5 83055.7 76068.6












Figure 52. Graph Showing Stability Changes in Terms of Area Count for 17 Hydroxy 










































































































































































































































Table AV: Stability Changes with Respect to Area Count for Medroxyprogesterone 




7 14 21 28
H20 spike +4 °C A 145185.6 NA 104132.4 130941.2
H20 spike +4 °C B 162196.9 NA 96704.7 130250.3
H20 spike +4 °C A 128253.0 NA 58656.5 83472.3
H20 spike +4 °C B 126753.7 97700.0 59491.9 73212.7
H20 spike -20° C A NA NA 67673.6 90538.7
H20 spike -20° C B 247520.2 NA 67531.7 93742.0
H20 spike -20° C A 94185.7 55908.1 48082.6 62132.4
H20 spike -20° C B 87246.6 55101.2 52800.2 70231.2
Urine Spike  +4 °C A 134781.2 NA 79165.1 138226.3
Urine Spike  +4 °C B 165930.2 NA 102124.8 125435.2
Urine Spike  +4 °C A 160189.0 NA 146895.1 131160.0
Urine Spike  +4 °C B 152347.6 100974.0 115623.3 132311.7
Urine Spike  -20° C A 155453.5 NA 79736.7 95725.8
Urine Spike  -20° C B 137440.1 73905.1 163246.8 166315.9
Urine Spike  -20° C A NA 98460.4 144441.7 136879.8












Figure 53. Graph Showing Stability Changes in Terms of Area Count for 
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7 14 21 28
H20 spike +4 °C A 120871.2 NA 77189.7 112644.3
H20 spike +4 °C B 116820.4 NA 76952.1 107762.3
H20 spike +4 °C A 238609.3 NA 122955.2 197323.0
H20 spike +4 °C B 244756.0 235972.6 124881.7 173272.6
H20 spike -20° C A 675.4 NA 83895.2 110755.9
H20 spike -20° C B 216824.7 NA 79822.1 112541.2
H20 spike -20° C A 101734.1 88660.2 68346.6 100975.7
H20 spike -20° C B 94251.0 78223.1 70359.8 105094.3
Urine Spike  +4 °C A 511329.8 NA 381531.2 393516.8
Urine Spike  +4 °C B 530784.8 NA 696157.0 417041.9
Urine Spike  +4 °C A 523980.8 NA 803408.4 429346.3
Urine Spike  +4 °C B 526608.5 461698.5 606949.0 441819.5
Urine Spike  -20° C A 513149.8 NA 326317.6 272110.0
Urine Spike  -20° C B 653845.0 443228.9 542721.5 389901.7
Urine Spike  -20° C A 823015.0 457307.1 521614.9 390055.1












Figure 54. Graph Showing Stability Changes in Terms of Area Count for Cortisone 
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7 14 21 28
H20 spike +4 °C A 49575.2 NA 32140.5 45339.3
H20 spike +4 °C B 48190.0 NA 31461.4 42926.2
H20 spike +4 °C A 41857.8 NA 30568.6 46150.3
H20 spike +4 °C B 43333.2 37512.7 31072.5 39972.6
H20 spike -20° C A 350.6 NA 34634.8 45419.6
H20 spike -20° C B 95058.7 NA 33495.2 46462.0
H20 spike -20° C A 42237.3 37752.9 29184.9 40750.6
H20 spike -20° C B 41020.1 32630.8 30055.1 44858.7
Urine Spike  +4 °C A 110927.8 NA 76602.8 102204.4
Urine Spike  +4 °C B 115112.2 NA 54236.3 107078.4
Urine Spike  +4 °C A 124761.2 NA 63832.0 114891.6
Urine Spike  +4 °C B 122587.0 117332.1 78045.3 110869.5
Urine Spike  -20° C A 114456.3 NA 82112.7 71124.2
Urine Spike  -20° C B 98382.7 56222.2 130129.3 101754.6
Urine Spike  -20° C A NA 119073.7 127124.8 106563.8













Figure 55. Graph Showing Stability Changes in Terms of Area Count for 
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Table AY: Stability Changes with Respect to Area Count for 6α Methyl Prednisolone 




7 14 21 28
H20 spike +4 °C A 113378.8 NA 75492.0 121204.9
H20 spike +4 °C B 112071.4 NA 73658.8 118271.8
H20 spike +4 °C A 102022.9 NA 52094.5 116336.8
H20 spike +4 °C B 98132.0 97640.6 47620.7 100446.8
H20 spike -20° C A NA NA 74500.9 112727.1
H20 spike -20° C B 209258.5 NA 76811.3 117290.7
H20 spike -20° C A 105030.2 104978.9 63494.0 103501.4
H20 spike -20° C B 24074.1 92815.0 67301.8 108455.6
Urine Spike  +4 °C A 8969.9 NA 3512.9 4571.3
Urine Spike  +4 °C B NA NA 513.6 4744.6
Urine Spike  +4 °C A 9177.2 NA 666.4 6091.2
Urine Spike  +4 °C B 8440.3 6136.7 1829.0 5452.8
Urine Spike  -20° C A 7419.2 NA 2434.7 3306.494
Urine Spike  -20° C B 9623.2 2312.8 3063.0 3937.763
Urine Spike  -20° C A 246.3 6337.0 3323.1 4941.624













Figure 56. Graph Showing Stability Changes in Terms of Area Count for 6α Methyl 
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Table AZ: Stability Changes with Respect to Area Count for Medroxyprogesterone 




7 14 21 28
H20 spike +4 °C A 122476.4 NA 91205.2 105731.3
H20 spike +4 °C B 131873.1 NA 91944.2 108002.9
H20 spike +4 °C A 116741.5 NA 55314.0 61120.0
H20 spike +4 °C B 123287.9 119568.5 57265.4 55072.4
H20 spike -20° C A NA NA 62879.5 63062.7
H20 spike -20° C B 221403.5 NA 58449.4 64329.7
H20 spike -20° C A 76182.7 49984.7 38036.4 38215.0
H20 spike -20° C B 72012.8 51086.9 43565.7 43407.0
Urine Spike  +4 °C A 152957.1 NA 131660.2 151835.1
Urine Spike  +4 °C B 191419.5 NA 69116.1 137942.9
Urine Spike  +4 °C A 168111.7 NA 169678.5 132342.3
Urine Spike  +4 °C B 178050.6 129826.4 119560.5 136146.8
Urine Spike  -20° C A 181942.6 NA 146472.8 99596.6
Urine Spike  -20° C B 182030.4 174217.6 197144.5 166389.4
Urine Spike  -20° C A 195416.2 125979.1 176484.9 140824.7












Figure 57. Graph Showing Stability Changes in Terms of Area Count for 











































































































































































































































Table BA: Stability Changes with Respect to Area Count for Triamicinolone 




7 14 21 28
H20 spike +4 °C A 192978.0 NA 117552.3 131341.2
H20 spike +4 °C B 200173.8 NA 115620.1 131691.5
H20 spike +4 °C A 170704.1 NA 108547.7 124978.5
H20 spike +4 °C B 168354.4 171672.2 109297.7 110337.8
H20 spike -20° C A NA NA 120188.9 119474.3
H20 spike -20° C B 304181.9 NA 122284.0 121025.3
H20 spike -20° C A 162823.2 172229.5 100792.3 105900.2
H20 spike -20° C B 148548.9 153250.4 108875.4 102204.4
Urine Spike  +4 °C A 47484.6 NA 25703.5 22550.3
Urine Spike  +4 °C B 48289.1 NA NA 23956.7
Urine Spike  +4 °C A 54050.5 NA 23615.6 27473.2
Urine Spike  +4 °C B 55931.6 39207.6 26979.3 26837.8
Urine Spike  -20° C A 47164.1 NA 18536.0 24190.2
Urine Spike  -20° C B 25303.4 9447.1 22176.7 20991.7
Urine Spike  -20° C A NA 39237.2 27196.6 23347.5












Figure 58. Graph Showing Stability Changes in Terms of Area Count for 














































































































































































































































Table BB: Stability Changes with Respect to Area Count for Triamicinolone 




7 14 21 28
H20 spike +4 °C A 313218.8 NA 212570.8 131341.2
H20 spike +4 °C B 340688.6 NA 210151.4 131691.5
H20 spike +4 °C A 165223.7 NA 134691.8 124978.5
H20 spike +4 °C B 179826.7 155576.7 142045.7 110337.8
H20 spike -20° C A NA NA 214640.2 119474.3
H20 spike -20° C B 584165.2 NA 212734.8 121025.3
H20 spike -20° C A 294489.2 271387.4 176561.2 105900.2
H20 spike -20° C B 266293.5 240964.2 180218.1 102204.4
Urine Spike  +4 °C A 76147.1 NA 32325.0 22550.3
Urine Spike  +4 °C B 67924.9 NA 14679.1 23956.7
Urine Spike  +4 °C A 84263.8 NA 19625.7 27473.2
Urine Spike  +4 °C B 88103.0 60139.8 32288.9 26837.8
Urine Spike  -20° C A 74913.6 NA 34497.0 24190.2
Urine Spike  -20° C B 58911.0 20308.1 43966.8 20991.7
Urine Spike  -20° C A 8718.5 63001.7 53638.8 23347.5












Figure 59. Graph Showing Stability Changes in Terms of Area Count for 


















































































































































































































































7 14 21 28
H20 spike +4 °C A 46390.1 30341.0 28308.1 22639.1
H20 spike +4 °C B 38247.1 23259.6 23377.4 23521.5
H20 spike +4 °C A 11649.5 11855.5 5347.1 4532.9
H20 spike +4 °C B 11376.0 13033.1 5319.0 3987.3
H20 spike -20° C A 74510.5 78804.8 36876.9 44357.8
H20 spike -20° C B 65593.8 72158.6 38732.7 44062.0
H20 spike -20° C A 113337.2 115083.0 93936.2 91445.3
H20 spike -20° C B 120486.4 117855.7 94103.8 87681.5
Urine Spike  +4 °C A 8172.9 8896.7 7978.4 10426.9
Urine Spike  +4 °C B 8962.2 10433.0 8647.6 10835.2
Urine Spike  +4 °C A 11247.6 12043.4 13914.7 16814.1
Urine Spike  +4 °C B 12320.9 13073.7 13582.7 16903.6
Urine Spike  -20° C A 8562.8 4578.9 7957.6 10010.5
Urine Spike  -20° C B 9009.5 5416.2 6801.6 8804.1
Urine Spike  -20° C A 13940.5 1356.2 9336.3 11909.9














Figure 60. Graph Showing Stability Changes in Terms of Area Count for 



























7 14 21 28
H20 spike +4 °C A 77931.6 40000.6 33918.8 32654.7
H20 spike +4 °C B 50989.5 28945.6 30292.3 32371.4
H20 spike +4 °C A 17402.9 21275.7 8646.5 9359.0
H20 spike +4 °C B 17334.4 24227.7 7452.3 9835.3
H20 spike -20° C A 128569.8 145907.4 49886.4 69721.3
H20 spike -20° C B 118648.6 127978.9 54078.1 69510.6
H20 spike -20° C A 194314.7 210238.5 137821.7 155857.4
H20 spike -20° C B 201493.5 203777.5 136942.5 147831.6
Urine Spike  +4 °C A 8798.2 10331.6 4563.9 7133.4
Urine Spike  +4 °C B 4432.4 9994.5 4983.3 5136.3
Urine Spike  +4 °C A 11338.4 10091.8 9207.6 53161.9
Urine Spike  +4 °C B 13141.0 12089.0 3737.9 51751.4
Urine Spike  -20° C A 8126.5 8068.2 4478.7 4525.2
Urine Spike  -20° C B 8075.5 8128.5 4827.0 4958.7
Urine Spike  -20° C A 15950.3 426.9 7096.5 3875.7












Figure 61. Graph Showing Stability Changes in Terms of Area Count for Enoxacin 













































































































































































































































7 14 21 28
H20 spike +4 °C A 52654.6 32186.0 29666.4 27831.6
H20 spike +4 °C B 36881.2 18191.6 26085.5 27695.9
H20 spike +4 °C A 5493.6 12377.6 5300.6 3021.9
H20 spike +4 °C B 5302.5 13750.1 5044.7 3105.5
H20 spike -20° C A 61925.9 81270.0 30334.9 35764.2
H20 spike -20° C B 57114.5 73107.4 31243.6 37985.9
H20 spike -20° C A 97271.2 118617.1 93691.3 88194.6
H20 spike -20° C B 101481.5 115743.7 92621.8 83717.7
Urine Spike  +4 °C A 7149.8 10952.2 8897.2 13992.5
Urine Spike  +4 °C B 8202.3 9439.4 9205.1 13085.2
Urine Spike  +4 °C A 9979.0 11875.4 13134.4 18200.1
Urine Spike  +4 °C B 10463.9 12140.5 12936.7 17348.1
Urine Spike  -20° C A 8692.9 6383.2 8879.6 12019.1
Urine Spike  -20° C B 8050.8 6082.7 7960.9 11130.8
Urine Spike  -20° C A 13939.4 226.6 9474.0 13050.2














Figure 62. Graph Showing Stability Changes in Terms of Area Count for Pefloxacin 












































































































































































































































7 14 21 28
H20 spike +4 °C A 131920.9 86450.0 76345.4 75254.4
H20 spike +4 °C B 92647.3 56581.7 72619.6 79216.5
H20 spike +4 °C A 44702.2 57583.3 21760.2 27917.3
H20 spike +4 °C B 47570.7 62222.0 24694.5 21429.6
H20 spike -20° C A 167776.6 174892.4 76881.3 94183.6
H20 spike -20° C B 138837.1 170354.5 79675.6 95314.6
H20 spike -20° C A 271455.4 266014.1 232222.3 232240.9
H20 spike -20° C B 277734.0 289514.1 238888.7 226308.2
Urine Spike  +4 °C A 10846.3 11937.3 9788.2 11457.4
Urine Spike  +4 °C B 10848.5 12544.3 9465.1 11590.6
Urine Spike  +4 °C A 14896.7 16744.3 17420.5 20554.1
Urine Spike  +4 °C B 15647.2 16494.9 17794.4 19210.5
Urine Spike  -20° C A 11185.0 8509.7 9477.3 10125.9
Urine Spike  -20° C B 10867.2 7782.7 8664.5 9595.3
Urine Spike  -20° C A 18853.4 NA 11953.6 15092.6












Figure 63. Graph Showing Stability Changes in Terms of Area Count for 













































































































































































































































7 14 21 28
H20 spike +4 °C A 347497.8 391650.0 295005.5 299705.3
H20 spike +4 °C B 298680.9 132999.4 271545.6 299339.3
H20 spike +4 °C A 464688.9 565443.5 354098.7 376795.9
H20 spike +4 °C B 460115.0 573218.6 350641.5 327671.8
H20 spike -20° C A 353398.1 436953.1 224787.8 264858.1
H20 spike -20° C B 307437.8 413646.6 227340.0 255538.6
H20 spike -20° C A 408004.3 497942.7 373675.7 376699.6
H20 spike -20° C B 405871.2 496641.9 386588.0 369775.3
Urine Spike  +4 °C A 100623.6 103450.8 71215.8 77346.2
Urine Spike  +4 °C B 98311.3 109968.9 72351.7 69388.9
Urine Spike  +4 °C A 130813.6 141057.9 125708.6 126161.6
Urine Spike  +4 °C B 147938.7 137965.2 129423.1 114901.4
Urine Spike  -20° C A 107050.9 66783.2 74604.3 59838.8
Urine Spike  -20° C B 100917.2 70990.6 68993.4 60901.7
Urine Spike  -20° C A 175365.8 888.6 84078.3 75688.2












Figure 64. Graph Showing Stability Changes in Terms of Area Count for 
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7 14 21 28
H20 spike +4 °C A 271890.1 400263.7 461175.7 392125.0
H20 spike +4 °C B 471407.1 282332.4 381066.9 422301.9
H20 spike +4 °C A 54031.0 82647.2 43528.1 37186.5
H20 spike +4 °C B 51687.3 92562.0 33140.6 43657.0
H20 spike -20° C A 328984.3 430838.2 405431.5 501040.5
H20 spike -20° C B 311358.6 396591.4 463914.0 497139.0
H20 spike -20° C A 518629.8 609785.2 551935.1 524773.9
H20 spike -20° C B 536630.5 631018.5 550555.1 499805.4
Urine Spike  +4 °C A 2408445.5 2733270.3 2360236.7 3002243.4
Urine Spike  +4 °C B 2416707.9 2718924.0 2305433.7 3022227.9
Urine Spike  +4 °C A 2524567.4 2818029.2 2446280.2 3182208.5
Urine Spike  +4 °C B 2633920.8 2917863.4 2444767.6 3008674.4
Urine Spike  -20° C A 2496497.9 2059761.7 2283784.0 2744808.8
Urine Spike  -20° C B 2446422.1 2075296.5 2208589.8 2717278.2
Urine Spike  -20° C A 2299653.5 10734.4 2238192.3 2998699.3













Figure 65. Graph Showing Stability Changes in Terms of Area Count for Ofloxacin 










































































































































































































































7 14 21 28
H20 spike +4 °C A 273036.1 404237.8 465368.5 393401.2
H20 spike +4 °C B 472155.7 284580.9 379122.8 422345.0
H20 spike +4 °C A 54228.4 82759.5 43083.9 37090.7
H20 spike +4 °C B 51118.1 91666.4 32452.3 43606.3
H20 spike -20° C A 326531.1 425549.1 406899.4 505117.6
H20 spike -20° C B 310869.9 393082.2 465378.1 497225.3
H20 spike -20° C A 516855.7 611597.8 541805.0 523911.6
H20 spike -20° C B 527579.2 622033.1 542263.6 493392.7
Urine Spike  +4 °C A 2399934.9 2718966.4 2360501 2973505.1
Urine Spike  +4 °C B 2419329.1 2720549.5 2306328 2977582.7
Urine Spike  +4 °C A 2513663.3 2817030.0 2442487 3153811.6
Urine Spike  +4 °C B 2620636.7 2930804.8 2457382 3006217.6
Urine Spike  -20° C A 2475274.9 2055818.8 2282310 2743318.5
Urine Spike  -20° C B 2440115.4 2072775.3 2208983 2719787.2
Urine Spike  -20° C A 2314621.0 10830.7 2231959 3016969.3












Figure 66. Graph Showing Stability Changes in Terms of Area Count for 
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7 14 21 28
H20 spike +4 °C A 53049.8 NA 218264.5 256293.0
H20 spike +4 °C B 65057.5 NA 235551.4 233986.1
H20 spike +4 °C A 62311.0 NA 37443.1 5708.3
H20 spike +4 °C B 57667.3 105503.8 34327.9 6296.1
H20 spike -20° C A 64267.5 NA 201477.0 209999.8
H20 spike -20° C B 62223.4 169550.8 204615.8 235584.1
H20 spike -20° C A 71779.1 235456.5 243016.6 186513.4
H20 spike -20° C B 72150.7 186385.6 177234.4 172751.5
Urine Spike  +4 °C A 10376.6 NA 34443.3 25805.7
Urine Spike  +4 °C B 10308.9 NA 32856.3 26973.7
Urine Spike  +4 °C A 10695.5 25198.8 42536.6 24057.3
Urine Spike  +4 °C B 10825.6 23799.0 40753.0 25153.9
Urine Spike  -20° C A 10808.7 NA 32667.8 27099.3
Urine Spike  -20° C B 10743.9 30974.3 31659.6 28133.4
Urine Spike  -20° C A 19569.3 49949.8 48646.2 35349.5












Figure 67. Graph Showing Stability Changes in Terms of Area Count for 


















































































































































































































































7 14 21 28
H20 spike +4 °C A 61849.0 NA 36016.6 26166.2
H20 spike +4 °C B 72566.3 NA 42967.0 26917.0
H20 spike +4 °C A 182778.1 NA 159144.4 144417.3
H20 spike +4 °C B 151602.6 149647.4 146213.1 181867.9
H20 spike -20° C A 126908.8 NA 85970.8 105604.0
H20 spike -20° C B 130031.8 95408.0 100142.9 112338.6
H20 spike -20° C A 283974.4 253222.3 177872.5 185182.1
H20 spike -20° C B 310879.8 219965.9 190081.8 212974.9
Urine Spike  +4 °C A 82533.5 NA 60984.6 60905.9
Urine Spike  +4 °C B 86594.1 NA 63886.3 67558.3
Urine Spike  +4 °C A 130113.3 94047.1 118721.1 123011.3
Urine Spike  +4 °C B 121335.0 82751.4 118880.9 137416.0
Urine Spike  -20° C A 105127.9 NA 71951.5 69027.9
Urine Spike  -20° C B 94957.2 66476.1 65138.6 74918.4
Urine Spike  -20° C A 181750.6 127028.5 128607.2 127576.0












Figure 68. Graph Showing Stability Changes in Terms of Area Count for Lincomycin 



















































































































































































































































7 14 21 28
H20 spike +4 °C A 230001.1 NA 251948.9 324597.2
H20 spike +4 °C B 279698.8 NA 269904.2 282515.1
H20 spike +4 °C A 391843.9 NA 258335.8 173049.4
H20 spike +4 °C B 367136.3 323958.0 235234.3 184458.7
H20 spike -20° C A 266839.7 NA 227351.5 255304.0
H20 spike -20° C B 259196.2 202187.3 228915.8 281813.3
H20 spike -20° C A 251817.8 271208.0 254019.9 242417.3
H20 spike -20° C B 263486.3 215256.6 175970.7 204761.3
Urine Spike  +4 °C A 168817.2 NA 118928.9 117542.4
Urine Spike  +4 °C B 177827.1 NA 114686.2 125013.8
Urine Spike  +4 °C A 224875.3 158302.3 204106.2 213797.2
Urine Spike  +4 °C B 224792.4 149621.3 197340.3 223973.2
Urine Spike  -20° C A 186830.2 NA 115199.9 115801.7
Urine Spike  -20° C B 172920.3 115850.0 93396.3 122883.0
Urine Spike  -20° C A 360132.7 217797.5 210253.1 201656.2













Figure 69. Graph Showing Stability Changes in Terms of Area Count for 

















































































































































































































































7 14 21 28
H20 spike +4 °C A 74039.4 NA 77733.9 108591.1
H20 spike +4 °C B 90946.1 NA 75449.6 94290.4
H20 spike +4 °C A 126106.9 NA 75909.1 56693.3
H20 spike +4 °C B 115086.1 106031.8 67846.9 60352.7
H20 spike -20° C A 82992.5 NA 64458.5 81137.0
H20 spike -20° C B 80792.4 67213.2 69063.1 89101.0
H20 spike -20° C A 79139.2 91586.9 74160.2 75825.9
H20 spike -20° C B 82597.0 70471.2 56260.0 66571.5
Urine Spike  +4 °C A 52262.8 NA 38840.6 40115.7
Urine Spike  +4 °C B 57861.2 NA 31172.3 40952.9
Urine Spike  +4 °C A 71972.0 52797.1 57956.4 71211.0
Urine Spike  +4 °C B 69860.4 49034.1 49531.9 77834.0
Urine Spike  -20° C A 54530.2 NA 35611.9 41421.3
Urine Spike  -20° C B 49656.0 38596.7 30081.3 42830.8
Urine Spike  -20° C A 102742.9 72343.4 65846.0 72063.1













Figure 70. Graph Showing Stability Changes in Terms of Area Count for 
















































































































































































































































7 14 21 28
H20 spike +4 °C A 64353.0 NA 72675.7 87465.2
H20 spike +4 °C B 76716.5 NA 75745.2 76196.3
H20 spike +4 °C A 70783.9 NA 57223.7 22211.3
H20 spike +4 °C B 70665.6 88828.2 52504.4 22300.8
H20 spike -20° C A 71641.0 NA 77312.5 74305.0
H20 spike -20° C B 79959.1 63772.6 74227.8 82523.4
H20 spike -20° C A 49338.7 70161.1 60522.2 44048.1
H20 spike -20° C B 48267.0 50775.6 42190.6 41978.1
Urine Spike  +4 °C A 179556.2 NA 124951.4 102108.7
Urine Spike  +4 °C B 194591.3 NA 118875.7 101645.3
Urine Spike  +4 °C A 251441.6 140873.9 211185.6 166300.9
Urine Spike  +4 °C B 245533.8 129474.3 198778.5 183092.3
Urine Spike  -20° C A 207751.3 NA 121280.8 97963.7
Urine Spike  -20° C B 193002.3 103431.4 101004.8 100742.1
Urine Spike  -20° C A 402123.9 189901.4 212749.1 172151.3












Figure 71. Graph Showing Stability Changes in Terms of Area Count for 
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7 14 21 28
H20 spike +4 °C A 9461.9 NA 11955.5 10691.9
H20 spike +4 °C B 11261.7 NA 12414.1 9138.2
H20 spike +4 °C A 1788.3 NA 4032.4 4293.4
H20 spike +4 °C B 1690.9 9577.0 4189.4 7572.3
H20 spike -20° C A 12203.1 NA 13324.2 10418.1
H20 spike -20° C B 10910.0 10121.3 13275.0 11904.3
H20 spike -20° C A 7882.5 22028.6 20269.9 12202.7
H20 spike -20° C B 9114.5 17039.0 12115.2 8143.1
Urine Spike  +4 °C A 559.7 NA NA NA
Urine Spike  +4 °C B 708.0 NA NA NA
Urine Spike  +4 °C A 820.3 NA NA NA
Urine Spike  +4 °C B 751.8 NA NA NA
Urine Spike  -20° C A 473.8 NA NA NA
Urine Spike  -20° C B 478.0 NA NA NA
Urine Spike  -20° C A 980.4 NA NA NA













Figure 72. Graph Showing Stability Changes in Terms of Area Count for Spiramycin 
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